Check for updates

OPEN ACCESS

EDITED BY Joanne Paton, University of Plymouth, United Kingdom

REVIEWED BY Zulfiqarali Abbas, Muhimbili University of Health and Allied Sciences, Tanzania Peter Fasching, Vienna Health Association, Austria

*CORRESPONDENCE Sonal Sekhar Miraj Sonal.sekhar@manipal.edu

This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology

SPECIALTY SECTION RECEIVED 28 January 2023 ACCEPTED 14 March 2023 PUBLISHED 29 March 2023

CITATION

Kurian SJ, Baral T, Unnikrishnan MK, Benson R, Munisamy M, Saravu K, Rodrigues GS, Rao M, Kumar A and Miraj SS (2023) The association between micronutrient levels and diabetic foot ulcer: A systematic review with meta-analysis. *Front. Endocrinol.* 14:1152854. doi: 10.3389/fendo.2023.1152854

COPYRIGHT

© 2023 Kurian, Baral, Unnikrishnan, Benson, Munisamy, Saravu, Rodrigues, Rao, Kumar and Miraj. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

The association between micronutrient levels and diabetic foot ulcer: A systematic review with meta-analysis

Shilia Jacob Kurian^{1,2}, Tejaswini Baral^{1,2}, Mazhuvancherry K. Unnikrishnan³, Ruby Benson¹, Murali Munisamy⁴, Kavitha Saravu^{2,5}, Gabriel Sunil Rodrigues⁶, Mahadev Rao¹, Amit Kumar⁷ and Sonal Sekhar Miraj^{1,2*}

¹Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of High Education, Manipal, Karnataka, India, ²Manipal Centre for Infectious Diseases, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka, India, ³NGSM Institute of Pharmaceutical Sciences, NITTE (Deemed to be University), Mangalore, Karnataka, India, ⁴Department of Translational Medicine, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India, ⁵Department of Infectious Diseases, Kasturba Medical College and Hospital, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India, ⁶Department of General & Laparoscopic Surgery, Aster Al Raffah Hospital, Sohar, Oman, ⁷Department of Laboratory Medicine, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India

Background: Diabetic foot ulcers (DFU) are a major complication of diabetes mellitus (DM). Nutrient deficiencies are among the major risk factors in DFU development and healing. In this context, we aimed to investigate the possible association between micronutrient status and risk of DFU.

Methods: A systematic review (Prospero registration: CRD42021259817) of articles, published in PubMed, Web of Science, Scopus, CINAHL Complete, and Embase, that measured the status of micronutrients in DFU patients was performed.

Results: Thirty-seven studies were considered, of which thirty were included for meta-analysis. These studies reported levels of 11 micronutrients: vitamins B9, B12, C, D, E, calcium, magnesium, iron, selenium, copper, and zinc. DFU, compared to healthy controls (HC) had significantly lower vitamin D (MD: -10.82 14 ng/ml, 95% CI: -20.47, -1.16), magnesium (MD: -0.45 mg/dL, 95% CI: -0.78, -0.12) and selenium (MD: -0.33 µmol/L, 95% CI: -0.34, -0.32) levels. DFU, compared to DM patients without DFU, had significantly lower vitamin D (MD: -5.41 ng/ml, 95% CI: -8.06, -2.76), and magnesium (MD: -0.20 mg/dL, 95% CI: -0.25, -0.15) levels. The overall analysis showed lower levels of vitamin D [15.55ng/ml (95% CI:13.44, 17.65)], vitamin C [4.99µmol/L (95% CI:3.16, 6.83)], magnesium [1.53mg/dL (95% CI:1.28, 1.78)] and selenium [0.54µmol/L (95% CI:0.45, 0.64)].

Conclusion: This review provides evidence that micronutrient levels significantly differ in DFU patients, suggesting an association between micronutrient status and risk of DFU. Therefore, routine monitoring and supplementations are warranted in DFU patients. We suggest that personalized nutrition therapy may be considered in the DFU management guidelines.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ display_record.php?RecordID=259817, identifier CRD42021259817.

KEYWORDS

diabetic foot ulcers, micronutrients, vitamins, minerals, risk

1 Introduction

Chronic wound infections pose a significant health concern, especially diabetic foot ulcers (DFU) with maximum severity. It is estimated that foot ulcer complications account for 24.4% of healthcare costs among diabetics (1). The rising prevalence of diabetes projects DFU as a growing health concern that accounts for maximum non-traumatic amputation globally. Prevalence of DFU among diabetics has risen from 15 - 25% to 19 - 35% (2). The global prevalence of DFU is 6.3%, higher in males and type 2 diabetes mellitus (DM) than in females and type 1 DM (3). A recent study reported the one-, two -, and five-year survival rates in DFU patients as 81%, 69%, and 29%, indicating the robust association with mortality (4). Foot ulcers are less likely to heal in diabetics because of disorders in the intrinsic wound-healing process, such as compromised collagen cross-linking, altered functioning of matrix metalloproteinases, and immunological reasons (5). Management strategies include patient education, wound dressings, debridement, adequate offloading, blood sugar control, infection management, revascularisation, and advanced therapies (6, 7).

Nutrient deficiencies are among the major risk factors in DFU development and healing. Nutrient deficiencies modify the physiological responses to infection by diminishing the immune response, predisposing the skin to become thin and flaky, thereby developing a wound. The deficiencies also decrease subcutaneous fat at pressure points, together exacerbating the vulnerability to pressure wounds. Nutrient deficiencies also reduce the collagen synthesis required for wound healing and promote immobility due to diminished energy reserves (8). Malnutrition adversely affects the complex wound-healing process.

Hyperglycaemia and glucose-lowering drugs alter nutrient absorption in DM patients, resulting in nutritional deficiencies (9). Oxidative stress from glucose metabolism in DM depletes the natural antioxidant reserves of vitamins A, C, and E (9). Persistent hyperglycaemia and open wounds push the body into a catabolic state. As a result of insulin deprivation, negative nitrogen balance develops from gluconeogenesis from protein breakdown. Altered nutritional status and systemic deficiencies impair fibroblast, protein, and collagen synthesis (5). Micronutrients affect wound healing comprehensively, *via* antioxidant and anti-inflammatory action, collagen stabilization, cell growth regulation, and differentiation. A closer monitoring of micronutrient status in DFU is warranted, as nutrient status is an easily modifiable factor as compared to non-modifiable factors such as age, DM duration, metabolic factors, and micro-, and macro-vascular disorders. The focus of this study was to systematically review the literature and provide the nature of nutritional deficiencies in DFU patients as compared to DM and non-diabetic healthy controls (HC). This would help identify the primary micronutrient deficiencies in DFU patients and initiate supplementations accordingly. Therefore, we have collated and analysed multiple data related to micronutrient status in patients with DFU, DM, and healthy controls (HC).

2 Methods

This systematic review appraises the association between micronutrient status and the risk of DFU. We have followed the preferred reporting items for systematic review and meta-analysis (PRISMA) 2020 guidelines and developed the research question using the PECOS format: The original research articles (study design) among DFU patients (participants), micronutrient status (exposure) as a risk for foot ulcers (outcome) compared to the control groups (comparator). The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO), identification number CRD42021259817 (https://www.crd.york.ac.uk/PROSPERO/display_record.php? RecordID=259817).

2.1 Search strategy

Initial search was performed in July 2021 and updated on 21st October 2021. We systematically searched and identified relevant studies from the following databases: PubMed, Web of Science, Scopus, CINAHL Complete, and Embase. The references cited by the included articles were examined to identify more articles. We used the following search terms: 'micronutrient*', 'nutrient*', 'nutritional status', 'trace element*', 'vitamin*', 'provitamin*', 'mineral', 'diabetic foot ulcer*', 'DFU', 'diabetic foot infection*', 'diabetic foot osteomyelitis', 'diabetic foot', 'diabetic feet' combined using 'AND' and 'OR', without restrictions on date of publication and language.

2.2 Eligibility and study selection

The study titles and abstracts were initially screened, and full texts were examined for potential eligibility. We included studies published in English and all original research studies (RCTs and observational studies) that measured micronutrient status in DFU without date restrictions. Only baseline data regarding the demographics and micronutrient levels in DFU patients were retrieved from RCTs. We excluded animal studies, editorials, case reports, case series, abstract-only papers, conference proceedings, and publications that did not measure micronutrient levels. After the initial search, all references were downloaded to Endnote X9.3.3 software. Further, SJK and RB independently assessed the title and abstracts to check for eligibility based on inclusion and exclusion criteria. Disagreements were resolved by SSM.

2.3 Data extraction and quality assessment

Data from the included studies were extracted into a pre-framed data extraction sheet. The following variables were extracted: author name(s), year of publication, place of study, study design, patient demographic characteristics, number of patients in cases/control, sample size, DFU classification, and micronutrient assessed and status of micronutrient. SJK performed primary data extraction, which was cross-checked for accuracy by TB and RB. Disagreements were resolved by discussion/consultation with SSM. For RCTs, only the baseline micronutrient levels were extracted.

We used Cochrane risk-of-bias tool to assess the quality of RCTs, the Newcastle-Ottawa Scale (NOS) for observational studies (e.g., case-control and cohort studies), and Joanna Briggs Institute (JBI) critical appraisal checklist for cross-sectional studies. SJK and TB independently performed the quality assessment, and disagreements between reviewers were settled through consensus/ discussion with SSM.

2.4 Statistical analysis

From extracted data, we developed a narrative synthesis structured around micronutrient status, findings are presented in tabular form. We employed RevMan 5.4.1 software to perform meta-analysis of selected studies with quantitative estimation.

All data were systematically collected and converted to standard units to maintain uniformity of data using conversion tools (10). We used the statistics toolkit (STATTOOLS) developed by The Department of Obstetrics and Gynaecology of the Chinese University of Hong Kong (11) to combine the mean and standard deviation (SD), where cases or controls were categorized into multiple groups. The formula $SE = SD \div \sqrt{sample \quad size}$ was used to convert SD to standard error (SE) and vice versa as per Cochrane guideline (12).

Studies reporting vitamin E were excluded from the meta-analysis because we could not convert multiple units of measurement into a standardized uniform unit. Similarly, zinc values from Momen-Heravi et al. study were excluded from the meta-analysis (13). Unit mismatches could be due to the differences in analytical methods. We excluded vitamin D levels reported by Qasim et al. from the review because it had the lowest score in quality assessment (14). We also excluded vitamin D levels reported by Greenhagen et al. from metaanalysis because SD values were not mentioned (15).

The I² statistic was used to identify the heterogeneity among studies. A random-effects meta-analyses model was conducted because there was significant heterogeneity (I²>50%; P<0.01) in all the analyses performed. Subgroup analysis was carried out based on the geographical location, but not age and gender because of insufficient data.

2.5 Publication bias and sensitivity analysis

The publication bias was assessed using funnel plots. Based on the risk assessment scores, sensitivity analysis was performed to ensure the robustness of the data.


3 Results

We identified 1312 records from the databases listed. We identified four more relevant studies by manually searching literature references. We removed 553 duplicate records. The remaining 763 were screened based on title and abstract, of which 67 were selected for retrieval. Finally, a total of 46 articles were assessed for eligibility based on criteria, of which 9 were excluded as some were abstract only (n=3), baseline micronutrient levels were not reported (n=3), a specific micronutrient assessment was not made (n=1), low-quality assessment score (n=1), and an article was not in English. 37 were included in the review and 30 for meta-analysis. Figure 1: The PRISMA flow chart of study selection.

3.1 Study characteristics

A total of 37 articles were retrieved after a systematic literature search. Nine were RCTs (13, 16–23), and 28 were observational studies (15, 24–50) (12 cross-sectional, seven cohort, and nine case-control studies).

Nine (24.32%) each were reported from India (18, 25, 26, 30, 40, 47–50), and Iran (13, 16, 20–22, 24, 34, 39, 45), three (8.10%) from Turkey (27, 36, 43), two (5.40%) each from China (33, 37) and Nigeria (41, 42), and one (2.70%) each from Italy (19), Bulgaria (31), Greece (32), Pakistan (28), Bahrain (29), USA (15), Germany (38), Australia (35), Spain (44), Mexico (46), Denmark (17), and Slovakia (23). Number of DFU patients (men and women) ranged



assessment such as University of Texas Wound Classification System, Wagner's grading system, International Working Group on the Diabetic Foot (IWGDF) guideline 2019, and Armstrong classification of chronic wounds, and some were based on the clinical characteristics of the wound. These studies reported levels of 11 nutrients: vitamins B9, B12, C, D, E, calcium, magnesium, iron, selenium, copper, and zinc. Table 1 provides the study characteristics.

from 19 to 387. Multiple classification systems were used for DFU

3.2 Quality assessment

We employed the Cochrane risk-of-bias tool to assess the quality of RCTs. Case-control and cohort studies were assessed using the NOS. The overall NOS scores for the cohort and case-control studies were 5 to 7, and 6 to 8, respectively, indicating moderate quality. We used JBI checklist for cross-sectional studies. The highest and lowest scores were 8, and 2. Qasim et al. (lowest score) was excluded (14). Table 2 lists the Quality assessment scores of all included studies.

3.3 Meta-analysis

Micronutrient levels of DFU patients were compared against those with DM [Figure 2A] and HC [Figure 2B] and are reported in

Sl. no	Year, study title, place	Participants included	Micronutrients assessed	DFU assessment	Major findings
1.	2017 Momen- Heravi et al., Iran (12)	DFU- 60	Zinc	Wagner's grading system	Zinc supplementation significantly improved wound status and various biochemical markers.
2.	2019 Greenhagen et al., USA (14)	DFU-54 DM- 46	Vitamin D	NA	Significant VDD was identified in patients with various lower extremity complications, with and without ulcers.
3.	2019 Afzali et al., Iran (15)	DFU- 57	Magnesium	Wagner's grading system	Evident decrease in magnesium levels in DFU. Magnesium and vitamin E supplementation significantly improved wound healing and biochemical markers.
4.	2021 Halschou- Jensen et al., Denmark (16)	DFU- 48	Vitamin D	Based on clinical characteristics of the wound	VDD was markedly prevalent in DFU. High-dose vitamin D (6800IU/day) with standard care achieved a 100% median wound reduction.
5.	2020 Kamble et al., India (17)	DFU- 60	Vitamin D	Wagner's grading system	VDD was markedly prevalent in DFU. Vitamin D supplementation provided positive outcomes in wound healing and biochemical markers.
6.	2014 Maggi et al., Italy (18)	DFU- 30	Vitamin D	NA	VDD was markedly prevalent in the study population.

TABLE 1 Study Characteristics.

TABLE 1 Continued

SI. no	Year, study title, place	Participants included	Micronutrients assessed	DFU assessment	Major findings
7.	2018 Razzaghi et al., Iran (19)	DFU- 70	Magnesium	Wagner's grading system	Magnesium supplementation significantly improved wound status and various biochemical markers.
8.	2017 Razzaghi et al., Iran (20)	DFU- 60	Vitamin D	Wagner's grading system	VDD was markedly prevalent in the study population. Positive outcomes in wound healing and biochemical markers upon vitamin D supplementation.
9.	2016 Mozaffari- Khosravi et al., Iran (21)	DFU- 27	Vitamin D	Wagner's grading system	Both 150,000 and 300,000 IU of vitamin D improved ulcer characteristics, inflammatory, glycemic, and vitamin D status in DFU. 300,000 IU was found more effective than 150,000IU.
10.	2010 Palacka et al., Slovakia (22)	DFU- 59	Vitamin E	Wagner's grading system	Administration of polarised light along with antioxidant nutrients enhances outcomes in diabetic complications.
11.	2016 Afarideh et al., Iran (23)	DFU- 30 DM- 30 HC- 28	Vitamin D	University of Texas Wound Classification System	Serum 25(OH)D was higher in DFU than in DM and HC. Positive correlation between higher vitamin D levels and the risk of DFU.
12.	2019 Darlington et al., India (24)	DFU- 88 DM- 88	Vitamin D	Wagner's grading system	Vitamin D was less than 30ng/ml in 59.18% with a graft or achieved wound healing and in 97.44% of patients who either died or needed an amputation. 78.9% with healed wounds within six months had normal levels.
13.	2016 Gupta et al., India (25)	DFU- 50 DM- 50 HC- 25	Vitamin D	NA	Serum vitamin D levels were significantly lower in DFU than in controls. Vitamin D augments phagocytosis by macrophages and thereby enhances the innate immune response.
14.	2013 Keskek et al., Turkey (26)	DFU- 49 DM- 49 HC- 49	Magnesium	Based on clinical characteristics of the wound	A robust association between serum magnesium and incidence of DFU. Significantly lower magnesium in DFU compared to DM and HC.
15.	2020 Shaikh et al., Pakistan (27)	DFU- 387	Calcium	Wagner's grading system	Mini-nutritional assessment scores were correlated to DFU severity. No correlation between calcium levels and foot ulcers.
16.	2019 Smart et al., Bahrain (28)	DFU- 80	Vitamin D	Wagner's grading system	85% of study participants had <20ng/ml vitamin D. VDD to be included among the modifiable DFU aggravating factors.
17.	2012 Swain et al., India (29)	DFU- 74	Vitamin D Calcium	NA	Serum vitamin D < 20ng/ml; risk of vascular calcification higher with levels <10ng/ml.
18.	2020 Todorova et al., Bulgaria (30)	DFU- 73 DM- 169	Vitamin D	International Working Group on the Diabetic Foot guideline 2019	VDD significant in DFU. No significant difference in vitamin D levels between infected and uninfected ulcers.
19.	2020 Tsitsou et al., Greece (31)	DFU- 33 DM- 35 HC- 28	Vitamin D Calcium	Based on clinical characteristics of the wound	Significant VDD in diabetic patients with and without ulcers compared to HC

TABLE 1 Continued

SI. no	Year, study title, place	Participants included	Micronutrients assessed	DFU assessment	Major findings
20.	2020 Xiao et al., China (32)	DFU- 245 DM- 4039	Vitamin D	NA	Significant VDD in DFU patients.
21.	2021 Yarahmadi et al., Iran (33)	DFU- 32	Vitamin D	NA	Increased hs-CRP, prooxidant-antioxidant balance, and decreased vitamin D levels could affect the pathogenesis of DFU.
22.	2020 Brookes et al., Australia (34)	DFU- 48	Vitamin D Iron Zinc Selenium Vit C Vitamin B12	NA	More than 50% of participants had VDD and vitamin C deficiency. The risk of amputation is associated with lower levels of vitamin C, albumin, and hemoglobin. The duration of the ulcer is unaffected by nutritional markers.
23.	2018 Caglar et al., Turkey (35)	DFU- 58 DM- 47	Vitamin D	Wagner's grading system	Vitamin D significantly decreased in DFU; vitamin D supplements might avoid untoward immunological responses.
24.	2020 Dai et al., China (36)	DFU- 21 DM-30	Vitamin D	University of Texas Wound Classification System	VDD is a risk factor for DFU. A cut-off value of 13.68 ng/ml of 25 (OH) vitamin D as the threshold for DFU risk.
25.	2018 Feldkamp et al., Germany (37)	DFU- 104 DM- 103 HC- 99	Vitamin D	Armstrong classification of chronic wounds	Significant VDD in DFU patients; severe VDD in more than half, indicating DFU patients to be at risk for VDD.
26.	2019 Najafpour et al., Iran (38)	DFU- 35 DM- 35 HC- 35	Vitamin D	Wagner's grading system	Significant VDD in DFU patients. VDD is a risk factor for the development and formation of ulcers in DM.
27.	2013 Zubair et al., India (39)	DFU- 90162 DM- 162	Vitamin D	University of Texas Wound Classification System	Median vitamin D levels are lower in foot ulcer group than in controls. Multivariate analysis showed that low vitamin D predicted foot ulcers.
28.	2016 Bolajoko et al., Nigeria (40)	DFU- 70 HC- 50	Vitamin C Vitamin E Copper Zinc Selenium	Wagner's grading system	Vitamin C, vitamin E, and selenium are significantly lower in ulcer patients. But copper and zinc levels were similar for all participants.
29.	2012 Bosede et al., Nigeria (41)	DFU- 50 HC- 50	Selenium Vitamin C Vitamin E	Wagner's grading system	Vitamin C, vitamin E, and selenium lower in DFU than in HC.
30.	2013 Bozkurt et al., Turkey (42)	DFU- 50 DM- 50 HC- 100	Copper Zinc Magnesium	NA	Possible association between elevated zinc levels and DFU. Serum copper and zinc were higher in the DFU and DM than in HC (P<0.001). Serum magnesium was lower in all diabetic patients.
31.	2010 Gonz'alez et al., Spain (43)	DFU- 89 DM- 109	Folate Vitamin B12	Wagner's grading system	Vitamins folate and B12 levels were similar in both DFU and DM.
32.	2007 Larijani et al., Iran (44)	DFU- 19 DM- 20 HC- 20	Zinc	NA	Serum zinc is significantly lower in DFU; possibly contributing to the hyperactivity of polymorphonuclear leukocytes.

TABLE 1 Continued

Sl. no	Year, study title, place	Participants included	Micronutrients assessed	DFU assessment	Major findings
33.	2001 Rodrigues- Moran et al., Mexico (45)	DFU- 33 DM- 66	Magnesium	Based on clinical characteristics of the wound	Significantly lower serum magnesium levels among the DFU.
34.	2013 Tiwari et al., India (46)	DFU- 125 DM- 164	Vitamin D	NA	VDD was substantially more prevalent and severe in DFI than in controls. VDD is a possible risk factor. Initiating supplementation improves patient outcomes.
35.	2014 Tiwari et al., India (47)	DFU- 112 DM- 107	Vitamin D	Wagner's grading system	Severe VDD in DFI patients is also associated with increased inflammatory cytokines. A cut-off value of 10ng/ml of 25 (OH) vitamin D for immunological alterations in DM patients.
36.	2020 Yadav et al., India (48)	DFU- 32 DM- 32	Zinc, Magnesium Copper	Based on clinical characteristics of the wound	Serum zinc, copper, and magnesium levels were substantially reduced in DFU and also found to be inversely related to glycaemic parameters and directly proportional to the duration of DM.
37.	2008 Singh SK et al., India (49)	DFU- 32 DM- 15 HC- 15	Vitamin E	NA	Diabetic patients with PVD and foot ulcers had significantly lower antioxidant levels and vitamin E.

VDD, vitamin D deficiency; NA, not available; DFU, Diabetic Foot Ulcer; DFI, Diabetic Foot Infections; DM, Diabetes mellitus; HC, Healthy controls; PVD, Peripheral Vascular Disease.

mean differences (MD). Figure 3 presents the summary results of micronutrient levels in DFU patients.

3.3.1 Vitamin B

Gonzalez et al. estimated folic acid and vitamin B12 levels among DM (n= 109) and DFU (n= 89) patients (44). Serum folic acid (24.9 \pm 11.51 vs 25.8 \pm 16.6 nmol/L, *P* = 0.67), and vitamin B12 (392.6 \pm 242 vs 453.9 \pm 290.8 pmol/L, *P* = 0.15) were similar in both groups. Brookes et al. reported vitamin B12 in DFU (n= 39) patients with a mean 294.6 \pm 221.8 pmol/L (35). The pooled vitamin B12 level in DFU (n= 128) patients was 346.68 pmol/L, 95% CI: 250.83, 442.53; *P*<00001; *I*² = 80%.

3.3.2 Vitamin C

Two studies compared vitamin C in DFU (n=120) and HC (n= 100) patients (41, 42). Combined results showed no significant difference in vitamin C levels between the two groups (MD: -4.38 μ mol/L, 95% CI: -9.47, 0.71; *P*= 0.09; $I^2 = 99\%$). A total of three studies measured vitamin C in patients with DFU (35, 41, 42). The mean vitamin C level in DFU (n= 166) patients was 4.99 μ mol/L, 95% CI: 3.16, 6.83; *P*<00001; $I^2 = 96\%$.

3.3.3 Vitamin D

Thirteen studies compared vitamin D levels in DFU (n= 1136) and DM (n= 5059) patients (24–26, 31–33, 36–40, 47, 48). Combined results showed significantly lower vitamin D levels in DFU patients (MD: -5.41 ng/ml, 95% CI: -8.06, -2.76; P<0001; I^2 = 92%). Combined results of five studies in DFU (n= 252) and HC (n= 215) (24, 26, 32, 38, 39); show significantly lower vitamin D levels in DFU (MD: -10.82 14 ng/ml, 95% CI: -20.47, -1.16; P=0.03; I^2 = 96%). From 22 studies that measured vitamin D in

patients with DFU (n= 1433) (17–19, 21, 22, 24–26, 29–40, 47, 48), mean levels in patients were 15.55ng/ml, 95% CI: 13.44, 17.65; *P*<00001; I^2 = 97%. Greenhagen et al. reported 18.7ng/ml of vitamin D in 54 DFU patients compared to 23.6 ng/ml in DM (n= 46) patients without ulcers (15).

3.3.4 Vitamin E

Four studies estimated Vitamin E. Singh et al. measured vitamin E levels in DFU (n= 32) patients, DM (n= 15), and HC (n= 15) (50). Vitamin E levels were substantially lower in DFU, compared to DM (5.04 ± 1.76 vs. 9.10 ± 2.83 ng/L, P<0.001) and HC (10.68 ± 2.58 ng/L). Bolajoko et al. found lower vitamin E levels in DFU (n= 120) vs DM (n= 50) 19.57 ± 1.01 vs 25.57 ± 0.27 µmol/L, P=0.0001 (41). A study by Bosede et al. demonstrated no significant difference in vitamin E between DFU (n= 50) and HC (n=50) (0.05 ± 0.02 vs. 0.06 ± 0.005 mmol/L) (42). Palacka et al. assessed multiple baseline metabolic parameters in DFU patients, among which vitamin E was 18.48 \pm 7.62 mmol/L (23).

3.3.5 Calcium

Two studies compared calcium levels in DFU (n= 106) and DM (n= 204) patients (31, 32). The combined results showed similar calcium levels in both groups (MD: -0.17 mg/dL, 95% CI: -0.60, 0.26; P=0.43; I^2 = 92%). A total of four studies measured calcium in DFU (n=567) (28, 30–32), with mean levels of 9.10 mg/dL, 95% CI: 8.71, 9.49; P<00001; I^2 = 95%.

3.3.6 Magnesium

Combined results from 4 studies comparing magnesium levels in DFU (n= 164) and DM (n= 197) patients (27, 43, 46, 49); showed lower magnesium levels in DFU (MD: -0.20 mg/dL, 95% CI: -0.25,

RCT- Cochrane risk-of-bias							
Study	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting	Other bias
Momen-Heravi M_2017 (12)	Low	Unclear	Unclear	Unclear	Low	Low	Low
Afzali_2019 (15)	Low	High	Low	Low	Low	Low	Low
Halshchou-Jensen_2021 (16)	Low	Low	Unclear	Unclear	Low	Low	Low
Kamble_2020 (17)	High	High	High	High	Low	Low	Low
Maggi_2014 (18)	Low	High	Unclear	Unclear	Unclear	Low	Low
Razzaghi_2018 (19)	Low	Low	Unclear	Unclear	Low	Low	Low
Razzaghi_2017 (20)	Low	Low	Unclear	Unclear	Low	Low	Low
Mozaffari-Khosravi_2016 (21)	Low	High	Unclear	Unclear	Low	Low	Low
Palacka_2010 (22)	High	High	High	High	Unclear	Low	Unclear

Cohort study- Newcastle-Ottawa scale

Study	Selection				Comparability	Exposure			Final
	Representativeness Selection		Ascertainment	Demonstration	Comparability	Assessment	Duration	Adequacy	Score
Greenhagen_ 2019 (14)	0	0	1	1	2	1	0	0	5
Brookes_ 2020 (34)	1	0	1	0	2	1	0	0	5
Caglar_ 2018 (35)	1	1	1	1	1	1	0	0	6
Dai_ 2020 (36)	1	1	1	1	2	1	0	0	7
Feldkamp_ 2018 (37)	1	1	1	0	1	1	0	0	5
Najafpour_ 2019 (38)	1	1	1	0	1	1	0	0	5
Zubair_2013 (39)	1	1	1	1	2	1	0	0	7


Case-control study	y- Newcastle-Ottawa	scale								
Study	Selection				Comparability	Exposure			Final Score	
	Case definition	Representativeness	Selection of Controls	Definition of Controls	Comparability	Ascertainment	Method of ascertain- ment	Non-Respons	nse rate	
Bolajako_ 2016 (40)	1	1	1	1	2	1	0	0	7	
Bosede_ 2012 (41)	1	1	0	1	2	1	1	0	7	
Bozkurt_2013 (42)	0	1	0	1	2	1	1	0	6	
Gonz'alez_2010 (43)	1	1	0	1	2	1	1	1	8	
Larijani_2007 (44)	1	1	1	1	2	1	1	0	8	
Rodrigues- Moran_ 2001 (45)	1	1	1	1	2	1	1	0	8	
Tiwari_ 2013 (46)	1	1	0	1	0	1	1	1	6	
Tiwari_ 2014 (47)	1	1	1	1	0	1	1	0	6	
Yadav_ 2020 (48)	1	1	0	1	1	1	1	1	7	

Frontiers in Endocrinology

Cross-sectional study- Joanna Briggs Institute critical appraisal checklist

	Were the criteria for inclusion in the sample clearly defined?	Were the study subjects and the setting described in detail?	Was the exposure measured in a valid and reliable way?	Were objec- tive, standard criteria used for measure- ment of the condition?	Were confounding factors identi- fied?	Were strategies to deal with confounding factors stated?	Were the outcomes measured in a valid and reliable way?	Was appro- priate statis- tical analysis used?	
Qasim_ 2020 (13)	No	Yes	Unclear	No	No	No	Yes	Unclear	exclude
Afarideh_2016 (23)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Include
Darlington_2019 (24)	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Include
Gupta_ 2016 (25)	Unclear	Yes	Yes	Yes	No	No	Yes	Yes	Include
Kenskek_2013 (26)	No	Yes	Yes	Yes	No	No	Yes	Yes	Include
Shaikh_ 2020 (27)	Yes	Yes	Yes	Yes	No	No	No	Yes	Include

Smart_ 2019 (28)	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Include
Swain_ 2012 (29)	No	No	Yes	Yes	No	No	Yes	Yes	Include
Todorova_2020 (30)	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Include
Tsitsou_ 2020 (31)	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Include
Xiao_ 2020 (32)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Include
Yarahamadi_2021 (33)	No	Unclear	Yes	Yes	No	No	Yes	Yes	Include
Singh_ 2008 (49)	Unclear	Unclear	Yes	Yes	No	No	Yes	Yes	Include



Forest plot of pooled mean difference of micronutrient status in DFU patients compared to DM and HC (A) Micronutrient levels of DFU patients were compared against those with DM; (B) Micronutrient levels of DFU patients were compared against those with HC.

-0.15; P<00001; $I^2 = 0$ %). Combined results of two other comparison studies in DFU (n= 99) and HC (n= 149) patients (27, 43); showed lower magnesium levels in DFU patients (MD: -0.45 mg/dL, 95% CI: -0.78, -0.12; P=0.008; $I^2 = 96$ %). From total of six studies (16, 20, 27, 43, 46, 49], pooled magnesium level was 1.53mg/dL, 95% CI: 1.28, 1.78; P<00001; $I^2 = 99$ % in DFU (n= 291).

3.3.7 Iron

Only one study reported Iron levels. A retrospective analysis by Brookes et al. reported mean iron levels of $8.4 \pm 5.9 \ \mu mol/L$ in 29 DFU patients (35).

3.3.8 Selenium

Combined results of two studies comparing selenium in DFU (n=120) and HC (n=100) (41, 42); showed significant difference in selenium levels between both groups (MD: -0.33 µmol/L, 95% CI: -0.34, -0.32; P < 0.00001; $I^2 = 0\%$). A total of three studies measuring selenium in DFU (n=123) (35, 41, 42), reported mean levels of 0.54 µmol/L, 95% CI: 0.45, 0.64; P < 00001; $I^2 = 93\%$.

3.3.9 Copper

Combined results of two studies comparing copper levels in DFU (n=82) and DM (n=82) (43, 49) showed similar copper levels in both groups (MD: -49.53 μ g/dL, 95% CI: -104.74, 5.68; *P*= 0.08; I^2 = 94%). Combined results of two studies comparing copper levels in DFU (n= 120) and HC (n= 150) (41, 43); showed similar levels in both groups (MD: 5.52 μ g/dL, 95% CI: -13.40, 24.45; *P*=0.57; I^2 = 97%). Three studies measuring copper in DFU (n= 152) (41,

43, **49**), reported mean levels of 90.67 µg/dL, 95% CI: 74.07, 107.26; P<00001; I^2 = 96%.

3.3.10 Zinc

Combined results of three studies comparing zinc levels in DFU (n=101) and DM (n= 102) patients (43, 45, 49) showed similar levels in both groups (MD: -6.18 µg/dL, 95% CI: -44.20, 31.85; *P*=0.75; $I^2 = 98\%$). Combined results of three studies comparing zinc levels in DFU (n= 139) and HC (n=170) (41, 43, 45); showed similar levels in both groups (MD: 7.62 µg/dL, 95% CI: -18.31, 33.56; *P*= 0.56; $I^2 = 98\%$). A total of five studies measuring zinc in patients with DFU (n= 180) (35, 41, 43, 45, 49) reported overall level of 73.67 µg/dL, 95% CI: 43.98, 103.36; *P*<00001; $I^2 = 100\%$. One RCT by Momen-Heravi et al. on the effect of zinc supplements in DFU patients reported the baseline zinc level as 77 ± 9.60 mg/dL (13).

3.4 Subgroup analysis, sensitivity analysis, and publication bias

Due to insufficient data, subgroup analysis (based on geographic location) was conducted only for vitamin D, zinc, and calcium. The mean vitamin D levels [(Figure 4A] were not significantly different across Middle East, Europe, and Asia/ Pacific regions (P=0.96). Mean zinc levels [(Figure 4B] significantly differed between Middle East, Asia/Pacific, and African regions (P<0.0001). The mean calcium levels [(Figure 4C] differed significantly between Europe and Asia/ Pacific regions (P=0.006).

95% CI

Study or Subgroup 3.1.1 Vitamin D	Mean	SE	Weight	Mean IV, Random, 95% Cl	Mean IV, Random, 95% Cl
Afarideh 2016	16.8	3.33	1.7%	16.80 [10.27, 23.33]	-
Brookes 2020	18.55	1.7	2.2%	18.55 [15.22, 21.88]	· · ·
Caglar 2018	7.9	0.83	2.4%	7.90 [6.27, 9.53] 11.21 [9.00, 13.42]	•
Dai 2020 Darlington 2019	11.21 24.85	1.13 1.51	2.3% 2.3%	11.21 [9.00, 13.42] 24.85 [21.89, 27.81]	· · ·
Feldkamp 2018	24.85	1.01	2.3%	24.85 [21.89, 27.81] 11.80 [9.62, 13.98]	
Supta 2016	14.25	1.2	2.3%	14.25 [11.90, 16.60]	-
Halschou-Jensen 2021	22.04	1.5	2.3%	22.04 [19.10, 24.98]	-
Kamble 2020 Maggi 2014	19.5 12.4	1.35 1.07	2.3% 2.3%	19.50 [16.85, 22.15] 12.40 [10.30, 14.50]	1.7
Aozaffari-Khosravi 2016	25.41	17.87	0.2%	25.41 [-9.61, 60.43]	
lajafpour 2019	16.86	1.69	2.2%	16.86 [13.55, 20.17]	-
Razzaghi 2017	17.7	1.7	2.2%	17.70 [14.37, 21.03]	-
Smart 2019 Swain 2012	12.4 14.81	0.87	2.4% 2.4%	12.40 [10.69, 14.11] 14.81 [12.99, 16.63]	
iwari 2013	16.13	1.37	2.4%	16.13 [13.44, 18.82]	
iwari 2014	16.11	1.48	2.3%	16.11 [13.21, 19.01]	-
odorova 2020	11.87	0.62	2.4%	11.87 [10.65, 13.09]	•
sitsou 2020 Jao 2020	17.9 14.81	1.17 0.46	2.3% 2.4%	17.90 [15.61, 20.19] 14.81 [13.91, 15.71]	1.
aao 2020 'arahmadi 2021	25.3	3.54	2.4%	14.81 [13.91, 15.71] 25.30 [18.36, 32.24]	·
ubair 2013	8.23	0.12	2.4%	8.23 [7.99, 8.47] 15.55 [13.44, 17.65]	
Subtotal (95% CI)			47.7%	15.55 [13.44, 17.65]	•
Heterogeneity: Tau ² = 22.1 Test for overall effect: Z = 1				P < 0.00001); I ² = 97%	
3.1.2 Magnesium Afzali 2019	1.53	0.02	2.4%	1.53 [1.49, 1.57]	
Bozkurt 2013	1.15	0.04	2.4%	1.15 [1.07, 1.23]	•
Ceskek 2013	1.73	0.03	2.4%	1.73 [1.67, 1.79]	
Razzaghi 2018 Rodriguos Moran, 2001	2.05 1.48	0.03	2.4% 2.4%	2.05 [1.99, 2.11]	[
Rodrigues-Moran 2001 'aday 2020	1.48	0.06	2.4%	1.48 [1.36, 1.60] 1.23 [1.11, 1.35]	
subtotal (95% CI)			14.7%	1.23 [1.11, 1.35] 1.53 [1.28, 1.78]	
leterogeneity: Tau ² = 0.10 est for overall effect: Z = 1	; Chi² = 4 11.94 (P ·	24.16, d < 0.0000	lf = 5 (P • 1)	< 0.00001); l² = 99%	
.1.3 Calcium Shaikh 2020	8.96	0.12	2.4%	8.96 [8.72, 9.20]	
wain 2020	8.90	0.12	2.4%	8.53 [8.24, 8.82]	
odorova 2020	9.54	0.04	2.4%	9.54 [9.46, 9.62]	•
īsitsou 2020 Subtotal (95% CI)	9.3	0.09	2.4% 9.8%	9.30 [9.12, 9.48] 9.10 [8.71, 9.49]	1
Heterogeneity: Tau ² = 0.15 Fest for overall effect: Z = 4	; Chi² = 6 15.34 (P	0.53, df < 0.0000	= 3 (P <	9.10 [8.71, 9.49] 0.00001); l² = 95%	'
1.4 Vitamin B12 brookes 2020	294.6	05.50	0.401	294.60 [224.98, 364.22]	
Srookes 2020 Sonz'alez 2010		35.52			
	392.6	25.65	0.1%	392 60 [342 33 442 87]	•
Subtotal (95% CI)		25.65	0.1%	392.60 [342.33, 442.87] 346.68 [250.83, 442.53]	
Subtotal (95% CI) reterogeneity: Tau ² = 3842	2.20; Chi ²	= 5.00,	0.1% 0.1% df = 1 (P	392.60 [342.33, 442.87] 346.68 [250.83, 442.53]	, , , , , , , , , , , , , , , , , , ,
Subtotal (95% CI) Heterogeneity: Tau ² = 3842 Fest for overall effect: Z = 7 8.1.5 Zinc	2.20; Chi ^a 7.09 (P <	= 5.00, 0.00001	0.1% 0.1% df = 1 (P)	392.60 [342.33, 442.87] 346.68 [250.83, 442.53] = 0.03); I ² = 80%	;
Subtotal (95% CI) Heterogeneity: Tau ² = 3842 Test for overall effect: Z = 7 8.1.5 Zinc Bolajoko 2016	2.20; Chi ^a 7.09 (P < 97.86	= 5.00, 0.00001 0.18	0.1% 0.1% df = 1 (P) 2.4%	392.60 [342.33, 442.87] 346.68 [250.83, 442.53] = 0.03); I ² = 80% 97.86 [97.51, 98.21]	
aubtotal (95% CI) leterogeneity: Tau ² = 3842 est for overall effect: Z = 7 c.1.5 Zinc lolajoko 2016 lozkurt 2013	2.20; Chi ^a 7.09 (P < 97.86 87.07	= 5.00, 0.00001 0.18 3.48	0.1% 0.1% df = 1 (P) 2.4% 1.7%	392.60 [342.33, 442.87] 346.68 [250.83, 442.53] = 0.03); I ² = 80% 97.86 [97.51, 98.21] 87.07 [80.25, 93.89]	
iubtotal (95% Cl) leterogeneity: Tau ² = 3842 rest for overall effect: Z = 7 .1.5 Zinc totajoko 2016 kozkurt 2013 trookes 2020	2.20; Chi ^a 7.09 (P < 97.86	= 5.00, 0.00001 0.18	0.1% 0.1% df = 1 (P) 2.4%	392.60 [342.33, 442.87] 346.68 [250.83, 442.53] = 0.03); I ² = 80% 97.86 [97.51, 98.21]	
subtotal (95% CI) leterogeneity: Tau ² = 3842 "est for overall effect: Z = 7 .1.5 Zinc kolajoko 2016 kozkurt 2013 trookes 2020 arijani 2007 "adav 2020	2.20; Chi ² 7.09 (P < 97.86 87.07 69.3	= 5.00, 0.00001 0.18 3.48 3.92	0.1% 0.1% df = 1 (P) 2.4% 1.7% 1.6% 1.1% 2.1%	392.60 [342.33, 442.87] 346.68 [250.83, 442.53] = 0.03); l ² = 80% 97.86 [97.51, 98.21] 87.07 [80.25, 93.89] 69.30 [61.62, 76.96] 79.00 [67.32, 90.68] 35.18 [30.79, 39.57]	
subtotal (95% CI) leterogeneity: Tau ² = 3842 est for overall effect: Z = 7 .1.5 Zinc lotajoko 2016 lozkurt 2013 trookes 2020 arijani 2007 "adav 2020 subtotal (95% CI) leterogeneity: Tau ² = 1133	2.20; Chi ² 97.86 87.07 69.3 79 35.18 3.99; Chi ²	= 5.00, 0.00001 0.18 3.48 3.92 5.96 2.24 = 847.7	0.1% 0.1% df = 1 (P) 2.4% 1.7% 1.6% 1.1% 2.1% 8.8% 5, df = 4	392.60 [342.33, 442.87] 346.68 [250.83, 442.53] = 0.03); l ² = 80% 97.86 [97.51, 98.21] 87.07 [80.25, 93.89] 69.30 [61.62, 76.98] 79.00 [67.32, 90.68] 35.18 [30.79, 39.57] 73.67 [43.98, 103.36]	
bubtotal (95% CI) leterogeneity: Tau ² = 344, 'est for overall effect: Z = 7 i.1.5.Zinc kolajoko 2016 loozkurt 2013 trookes 2020 arijani 2007 'datav 2020 Uibtotal (95% CI) leterogeneity: Tau ² = 1133 est for overall effect: Z = 4 .1.6 Vitamin C	2.20; Chi ³ 7.09 (P < 97.86 87.07 69.3 79 35.18 3.99; Chi ³ 4.86 (P <	0.18 3.48 3.92 5.96 2.24 = 847.7 0.00001	0.1% 0.1% df = 1 (P)) 2.4% 1.7% 1.6% 1.1% 2.1% 8.8% 5, df = 4)	$\begin{array}{l} 392.60(342.33,442.87)\\ e10.03),l^2=80\%\\ \hline \\ 97.86(97.51,98.21)\\ 87.07(80.25,93.89)\\ 69.30(61.62,76.89)\\ 79.00(67.32,90.68)\\ 35.16(30.79,39.87)\\ 73.67(43.38,00.36)\\ 73.67(43.38,00.36)\\ (l^2<0.00001),l^2=100\%\\ \end{array}$	
ubutotal (95% CI) leterogeneity: Tau ² = 3842 set for overall effect: Z = 7 .1.5 Zinc tolajoko 2016 tockurt 2013 trockes 2020 anijani 2007 "adav 2020 subtotal (95% CI) leterogeneity: Tau ² = 1133 set for overall effect: Z = 4 .1.6 Vitamin C loajoko 2016	2.20; Chi ² 7.09 (P < 97.86 87.07 69.3 79 35.18 3.99; Chi ² 1.86 (P < 3.76	2 = 5.00, 0.00001 0.18 3.48 3.92 5.96 2.24 = 847.7 0.00001 0.05	0.1% 0.1% df = 1 (P)) 2.4% 1.7% 1.6% 1.1% 2.1% 8.8% '5, df = 4) 2.4%	392_60 [342.33, 442_87] 446.68 [250.83, 442_83] = 0.03); l ² = 80% 97.86 [97.51, 98.21] 67.07 [80.25, 93.89] 69.30 [61.62, 76.98] 79.00 [67.32, 90.95,7] 73.67 [43.98, 103.36] (P < 0.00001); l ² = 100%	
<pre>biubtotal (95% CI) teterogeneity: Tau² = 3844 teterogeneity: Tau² = 3844 teterogeneity: Tau² = 3844 telerogeneity: Tau² = 384 telerogeneity: Tau² = 1133 telerogeneity: Tau² = 1133 teleforversell effect: Z = 4 .1.6 Vitamin C tolajoko 2016 tosede 2012</pre>	2.20; Chi ² 7.09 (P < 97.86 87.07 69.3 79 35.18 3.99; Chi ² 4.86 (P < 3.76 3	2 = 5.00, 0.00001 0.18 3.48 3.92 5.96 2.24 2 = 847.7 0.00001 0.05 0.28	0.1% 0.1% df = 1 (P)) 2.4% 1.7% 1.6% 1.1% 2.1% 8.8% '5, df = 4) 2.4% 2.4%	$\begin{array}{l} 392.60 \left(542.33, 442.87 \right) \\ e^{-5} \left(642.53, 442.53 \right) \\ e^{-5} \left(652.54, 442.53 \right) \\ e^{-5} \left(652.54, 652$	
Lubtotal (95% CI) leterogeneity: Tar = 3844 'est for overall effect: Z = 3 .1.5 Zinc tolajoko 2016 tozkurt 2013 trookes 2020 arijani 2007 'adav 2020 Lubtotal (95% CI) leterogeneity: Tar = 1133 'est for overall effect: Z = 4 .1.6 Vitamin C tolajoko 2016 tookes 2020	2.20; Chi ² 7.09 (P < 97.86 87.07 69.3 79 35.18 3.99; Chi ² 1.86 (P < 3.76	2 = 5.00, 0.00001 0.18 3.48 3.92 5.96 2.24 = 847.7 0.00001 0.05	0.1% 0.1% df = 1 (P)) 2.4% 1.7% 1.6% 1.7% 2.1% 8.8% (5, df = 4)) 2.4% 2.4% 1.9%	392_60 [342.33, 442_87] 446.68 [250.83, 442_83] = 0.03); l ² = 80% 97.86 [97.51, 98.21] 67.07 [80.25, 93.89] 69.30 [61.62, 76.98] 79.00 [67.32, 90.95,7] 73.67 [43.98, 103.36] (P < 0.00001); l ² = 100%	
ububcial (95% C)) detrogramity: Taa' = 384/3 est for overall effect. Z = 7 4.1.5 Zinc look/act 2013 took/act 2013 took/act 2013 took/act 2020 arijani 2007 dav 2020 ububcial (95% C)) detrogramity: Taa' = 113 est for overall effect. Z = 4 4.1.6 Vitano in C lossede 2012 took/act 2015 took/act 2012 took/act 2015 took/act 2012 took/act 2013 took/act 20	2.20; Chi ² 7.09 (P < 97.86 87.07 69.3 79 35.18 3.99; Chi ² 4.86 (P < 3.76 3 22.6 ; Chi ² = 4	2 = 5.00, 0.00001 0.18 3.48 3.92 5.96 2.24 2 = 847.7 0.00001 0.05 0.28 2.93 8.58, df	0.1% 0.1% df = 1 (P) 2.4% 1.7% 1.6% 1.1% 2.1% 8.8% 5, df = 4) 2.4% 2.4% 1.9% 6.7% 5.7%	$\begin{array}{c} 392.60(342.33,442.87)\\ =0.03), P=80\%\\ \\ 97.86(97.51,96.21)\\ 87.07(80.225,93.89)\\ 69.30(61.62,76.89)\\ 59.30(61.62,76.89)\\ 53.16(80.27,76.89)\\ 53.16(80.27,76.89)\\ 53.16(80.27,76.89)\\ 53.16(80.27,89,87)\\ 73.67(43.86,103.36)\\ 10.26(43.86,103.36)\\ 3.76(13.66,3.86)\\ 3.00(24.3,355)\\ 22.60(16.86,28.34)\\ 4.99(16.6,6.33)\\ \end{array}$	
ubiotal (95% C)) deterogranity: Tau' = 344,4 est for overall effect. Z = 7 .1.5.Zinc look/act 2013 took/act 2013 took/act 2013 took/act 2013 ani/ani 2007 ani/ani 2007 ani/ani 2007 ani/act 2013 took/act 2013 took/act 2016 took/act 20	2.20; Chi ² 7.09 (P < 97.86 87.07 69.3 79 35.18 3.99; Chi ² 4.86 (P < 3.76 3 22.6 ; Chi ² = 4 5.34 (P <	= 5.00, 0.00001 0.18 3.48 3.92 5.96 2.24 = 847.7 0.00001 0.05 0.28 2.93 8.58, df 0.00001	0.1% 0.1% df = 1 (P) 2.4% 1.7% 1.6% 2.1% 8.8% 5, df = 4) 2.4% 2.4% 1.9% 2.4% 2.4% 5, df = 2 (P <)	392.60 (342.33, 442.87) 446.68 (250.83, 442.87) 97.86 (97.51, 96.21) 87.07 (80.25, 93.69) 69.30 (16.25, 93.69) 79.00 (67.32, 90.68) 35.16 (30.77, 93.957) 73.67 (43.98, 103.36) (P< < 0.0001); P = 100% 3.76 (13.66, 8.38) 0.00001); P = 96%	
Liebtotal (195% C) Liebtorganeity: Tau' = 394/ est for overall effect. Z = 7 .1.5 Zine .1.5	2.20; Chi ² 7.09 (P < 97.86 87.07 69.3 79 35.18 3.99; Chi ² 4.86 (P < 3.76 3 22.6 ; Chi ² = 4 5.34 (P < 0.48	2 = 5.00, 0.00001 0.18 3.48 3.92 5.96 2.24 2 = 847.7 0.00001 0.05 0.28 2.93 8.58, df 0.00001	0.1% 0.1% df = 1 (P) 2.4% 1.6% 1.6% 2.1% 8.8% 5. df = 4) 2.4% 2.4% 1.9% 6.7% = 2 (P <) 2.4%	$\begin{array}{l} 392.60 \left[542.33, 442.87 \right] \\ 446.68 \left[220.83, 442.87 \right] \\ 97.86 \left[97.51, 98.21 \right] \\ 87.07 \left[80.25, 93.89 \right] \\ 69.30 \left[61.62, 76.88 \right] \\ 93.00 \left[67.32, 90.68 \right] \\ 73.67 \left[30.62, 76.89 \right] \\ 73.67 \left[30.62, 76.89 \right] \\ 74.67 \left[$	
Liebtotal (195%, C) Liebtorganeity: Tau' = 394, 4 est for overall effect: Z = 7 .1.5 Zinc loojkok 2016 loojkok 2016 lookat: 2013 lookat: 2013 lookat: 2013 lookat: 2013 lookat: 2013 lookat: 2013 lookat: 2016 lookat: 2017	2.20; Chi ² 7.09 (P < 97.86 87.07 69.3 79 35.18 3.99; Chi ² 4.86 (P < 3.76 3 22.6 ; Chi ² = 4 5.34 (P <	= 5.00, 0.00001 0.18 3.48 3.92 5.96 2.24 = 847.7 0.00001 0.05 0.28 2.93 8.58, df 0.00001	$\begin{array}{c} 0.1\%\\ 0.1\%\\ 0.1\%\\ df=1 \ (P\\)\\ \end{array}$	$\begin{array}{l} 392.60 \left(542.33, 442.87 \right) \\ 446.68 \left(250.08, 442.83 \right) \\ 97.86 \left(97.51, 98.21 \right) \\ 87.07 \left(80.25, 93.89 \right) \\ 69.30 \left(61.62, 76.89 \right) \\ 59.30 \left(61.62, 76.89 \right) \\ 53.61 \left(80.37, 79.90, 27.89, 57 \right) \\ 73.67 \left(33.6, 93.87 \right) \\ 73.67 \left(33.6, 33.87 \right) \\ 73.67 \left(34.8, 103.36 \right) \\ 1000 \left(73.32, 90.68 \right) \\ 3.76 \left(34.6, 3.35 \right) \\ 22.60 \left(16.86, 28.34 \right) \\ 4.99 \left(146, 6.43 \right) \\ 4.99 \left(146, 6.43 \right) \\ 0.46 \left(0.42, 0.59 \right) \\ 1.10 \left(0.48, 1.34 \right) \\ \end{array}$	
Liebtotal (25% C) Liebtorganeity: Tau" = 34/4 est for overall effect: Z = 7 1.5 Zine displace 2016 totalized totalized zina zin	2.20; Chi ² 7.09 (P < 97.86 87.07 69.3 79 35.18 3.99; Chi ² 4.86 (P < 3.76 3.22.6 ; Chi ² = 4 5.34 (P < 0.48 0.46 1.1	= 5.00, 0.00001 0.18 3.48 3.49 2.24 = 847.7 0.00001 0.05 0.28 2.93 8.58, df 0.00001 0.02 0.02 0.02	$\begin{array}{c} 0.1\%\\ 0.1\%\\ df=1 \left(P \right) \\ 2.4\%\\ 1.7\%\\ 1.1\%\\ 2.1\%\\ 1.1\%\\ 2.1\%\\ 5.5 \ df=4 \\ 1.9\%\\ 6.7\%\\ e=2 \left(P < \right) \\ \end{array}$	$\begin{array}{c} 392.60 \left(542.33, 442.87 \right) \\ = 0.03), l^2 = 80\% \\ \\ \hline 97.86 \left(97.08, 442.33 \right) \\ = 0.03), l^2 = 80\% \\ \\ \hline 97.86 \left(97.51, 98.21 \right) \\ 97.07 \left(80.25, 93.89 \right) \\ 95.30 \left(81.52, 93.89 \right) \\ 95.30 \left(81.52, 93.89 \right) \\ 79.00 \left(87.32, 90.68 \right) \\ 35.16 \left[50.77, 93.957 \right] \\ 73.87 \left[43.98, 103.36 \right] \\ 3.00 \left[24.53, 355 \right] \\ 22.60 \left[146.8, 28.34 \right] \\ 4.99 \left[3.16, 6.83 \right] \\ 4.99 \left[3.16, 6.83 \right] \\ 4.99 \left[3.16, 6.83 \right] \\ 0.48 \left[0.48 \right] \\ 0.48 \left[0.48 \right] 0.48 \\ 0.48 \left[0.48, 0.48 \right] \\ 0.64 \left[0.42, 0.50 \right] \\ 1.10 \left[0.56 \right] \\ 5.56 \right] \\ \end{array}$	
Liebtotal (195% C) Liebtorganeity: Tau' = 344,4 est for overall effect: Z = 7 1.5 Zinc loojkoto 2016 loojkoto 2016 loojkoto 2016 loojkoto 2016 loojkoto 2016 loojkoto 2016 loosdet 2020 loojkoto 2016 loosdet 2012 trockas 2020 loojkoto 2016 trockas 2020 loojkoto 2016 trockas 2020 loojkoto 2016 trockas	2.2.0; Chi ² 97.86 87.07 97.86 87.07 99.35.18 3.99; Chi ² 4 3.76 3.39; Chi ² 4 3.76 3.22.6 3.76 3.22.6 (Chi ² = 4 5.34 (P < 0.48 0.46 1.1	= 5.00, 0.00001 0.18 3.48 3.92 5.96 2.24 = 847.7 0.00001 0.05 2.93 8.58, df 0.00001 0.02 0.12 7.69, df	$ \begin{array}{c} 0.1\% \\ 0.1\% \\ df = 1 \left(P \right) \\ \end{array} \\ \begin{array}{c} 2.4\% \\ 1.7\% \\ 1.6\% \\ 1.1\% \\ 2.4$	$\begin{array}{c} 392.60 \left(542.33, 442.87 \right) \\ = 0.03), l^2 = 80\% \\ \\ \hline 97.86 \left(97.08, 442.33 \right) \\ = 0.03), l^2 = 80\% \\ \\ \hline 97.86 \left(97.51, 98.21 \right) \\ 97.07 \left(80.25, 93.89 \right) \\ 95.30 \left(81.52, 93.89 \right) \\ 95.30 \left(81.52, 93.89 \right) \\ 79.00 \left(87.32, 90.68 \right) \\ 35.16 \left[50.77, 93.957 \right] \\ 73.87 \left[43.98, 103.36 \right] \\ 3.00 \left[24.53, 355 \right] \\ 22.60 \left[146.8, 28.34 \right] \\ 4.99 \left[3.16, 6.83 \right] \\ 4.99 \left[3.16, 6.83 \right] \\ 4.99 \left[3.16, 6.83 \right] \\ 0.48 \left[0.48 \right] \\ 0.48 \left[0.48 \right] 0.48 \\ 0.48 \left[0.48, 0.48 \right] \\ 0.64 \left[0.42, 0.50 \right] \\ 1.10 \left[0.56 \right] \\ 5.56 \right] \\ \end{array}$	
bubbola (195%, C)) devogramity, Tau' = 394, fest for overall effect. Z = 7 1.1.5 Zinc bubbola 2016 bubbola 2016 bubbola 2017 factor 2020 bubbola (195%, C)) deterogeneity, Tau' = 1.83; deterogeneity, Tau' = 0.01; des for overall effect. Z = 1 bubbola 2012; dotseta 2012; dotset	2.2.0; Chi ² 97.86 87.07 69.3 79 35.18 3.99; Chi ² 1.86 (P < 3 3.76 3 3.76 3 3.76 3 3.22.6 3 3.22.6 3.34 (P < 0.48 0.46 1.1 1.37 (P -	= 5.00, 0.00001 0.18 3.48 3.92 5.96 2.24 = 847.7 0.00001 0.05 0.28 2.93 8.58, df 0.00001 0.02 0.12 7.69, df < 0.0000	$ \begin{array}{c} 0.1\% \\ 0$	$\begin{array}{l} 392.60 \left[342.33, 442.87 \right] \\ 446.68 \left[220.83, 442.87 \right] \\ 97.86 \left[97.51, 98.21 \right] \\ 87.07 \left[80.25, 93.89 \right] \\ 69.30 \left[61.62, 76.88 \right] \\ 69.30 \left[61.62, 76.88 \right] \\ 59.30 \left[61.62, 76.88 \right] \\ 51.81 \left[81.07, 94.87 \right] \\ 73.57 \left[13.68, 103.36 \right] \\ 173.57 \left[13.68, 103.36 \right] \\ 173.57 \left[13.66, 3.38 \right] \\ 3.76 \left[13.66, 3.38 \right] \\ 0.00001 \right]; P = 90\% \end{array}$	
bubbola (195% C)) devogramity: Tau' = 344/ test for ownall effect. Z = 7 1.1.5 Zinc bubbola 2010 bubbola 2010 bubbola 2010 devogramity: Tau' = 113/ test for ownall effect. Z = 4 1.1.6 Vitamin C test for ownall effect. Z = 4 1.1.6 Vitamin C bubbola 2010 bubbola 2010 bu	2.2.0; Chi ⁱ ¹ 97.86 67.07 69.3 79 35.18 3.99; Chi ² 3.76 3.76 3.37 6 3.37 6 3.37 6 3.37 6 3.37 6 3.37 6 3.37 6 3.37 6 3.37 6 3.37 6 3.37 6 3.37 6 3.37 7 9 2.2.6 1.11 7 9 2.71 1.12 7 2.8 7 9 2.71 1.12 7 2.8 7 9 2.71 7 2.8 7 9 2.71 7 7 2.8 7 9 2.71 7 7 9 2.71 7 7 9 2.71 7 7 9 2.71 7 7 9 2.71 7 7 9 2.71 7 7 9 3.5.18 7 9 3.5.19 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	<pre>1 = 5.00, 0.00001 0.18 3.48 3.92 5.96 2.24 1 = 847.7 0.00001 0.05 0.28 2.93 8.58, df 0.00001 0.02 0.12 7.69, df < 0.00001 0.24 3</pre>	$ \begin{array}{c} 0.1\% \\ 0.1\% \\ df = 1 \ (P \\) \end{array} \\ \begin{array}{c} 2.4\% \\ 1.7\% \\ 1.6\% \\ 1.1.7\% \\ 2.1\% \\ 8.8\% \\ 5.df = 4 \\) \end{array} \\ \begin{array}{c} 2.4\% \\ 7.4\% \\ 7.4\% \\ 2.4\% \\ 7.4\% \\ 1.9\% \\ 2.4\% \\ 1.9\% \\ 1.9\% \\ 1.9\% \\ 1.1\% \\ 1$	$\begin{array}{l} 392.60 (342.33, 442.87) \\ 446.68 (220.83, 442.87) \\ = 0.03); P = 80\% \\ \end{array}$	
Liebtotal (195% C) Liebtorganeity: Tau ² = 344,2 est for overall effect: Z = 7 1.1 3 Zine displace 2016 solidate 2010 torokes 2020 listotal (195% C) leterogeneity: Tau ² = 1 43 est for overall effect: Z = 7 1.3 Jine listotal (195% C) leterogeneity: Tau ² = 1 43 est for overall effect: Z = 6 1.3 Valuenti C lossicle 2012 torokes 2020 lubtotal (195% C) leterogeneity: Tau ² = 1 48 est for overall effect: Z = 6 listotal (195% C) leterogeneity: Tau ² = 1 48 est for overall effect: Z = 6 lossicle 2012 torokes 2020 lubtotal (195% C) leterogeneity: Tau ² = 1 67 est for overall effect: Z = 6 lossicle 2012 torokes 2020 lubtotal (195% C) leterogeneity: Tau ² = 0.01 est for overall effect: Z = 1 1.3 Cogneta displana 2016 lossicle 3012 torokes 1202	2.2.0; Chi ⁱ 97.86 87.07 (P 97.86 87.07 (P 97.86 93.3 99, Chi ⁱ 3.39; Chi ⁱ 3	<pre>' = 5.00, 0.00001 0.18 3.48 3.92 5.96 2.24 = 847.7 0.00001 0.05 0.28 2.93 8.58, df 0.00001 0.02 0.12 7.69, df < 0.00000 0.24</pre>	$ \begin{array}{c} 0.1\%\\ 0.1\%$	$\begin{array}{l} 392.60 (342.33, 442.87) \\ 446.68 (220.83, 442.87) \\ = 0.03); P = 80\% \\ \end{array}$	
Liebtotal (BS% C) Liebtorganeity: Tau' = 344,4 est for overall effect: Z = 7 .1.5 Zinc .1.5	2.20; Chil ⁱ 97.86 87.07 69.3 79 35.18 8.86 (P < 3.36 (P < 3.32.6 5.34 (P < 4.334 (P < 4.44 (P < 4.44 (P < 4.44 (P < 4.44 (P) 4.44 (P	2 = 5.00, 0.00001 0.18 3.48 3.92 5.96 2.24 1 = 847.7 0.00001 0.05 0.28 2.93 8.58, df 0.00001 0.02 0.12 7.69, df c.00000 0.24 3 9.17	$ \begin{array}{c} 0.1\%\\ 0.1\%$	$\begin{array}{l} 392.60 (342.33, 442.87) \\ 446.68 (250.83, 442.87) \\ 97.86 (97.51, 98.21) \\ 87.07 (80.25, 93.89) \\ 69.30 (61.62, 76.89) \\ 59.30 (61.62, 76.89) \\ 59.30 (61.62, 76.89) \\ 53.61 (80, 76.99, 89.7) \\ 73.67 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.6 (13.66, 3.8$	
bubbola (195%, C)) deterogramity: Trav = 394/2 deterogramity: Trav = 394/2 deterogramity: Trav = 394/2 bubbola 2010 terosher 2020 terosher 2020 terosher 2020 teterogramity: Trav = 1 13: deterogramity: Trav = 1 13: deterogramity: Trav = 1 13: deterogramity: Trav = 1 43: deterogramity: Trav = 0.01: deterogramity: Trav = 0.01: deterospectors: Trav = 0.01:	2.2.0; Chi ^j l P < 97.86 87.07 69.3 79 98.6 (P < 3.36, 18 3.99; Chi ^j = 4 3.76 3.34 (P < 0.48 0.46 1.1 ; Chi ^j = 2 11.37 (P · 92.71 72.8 112.33 83; Ch ^j ²	2 = 5.00, 0.00001 0.18 3.48 3.92 5.96 2.24 = 847.7 0.00001 0.02 0.28 2.93 8.58, df 0.00001 0.02 0.12 7.69, df < 0.0000 0.24 3 9.17 = 48.40,	0.1% 0.1% 0.1% 1.1% 1.7% 1.7% 1.7% 1.1% 2.4% 4.9% 2.4% 4.9% 2.4% 4.9% 2.4% 3.9%	$\begin{array}{l} 392.60 (342.33, 442.87) \\ 446.68 (250.83, 442.87) \\ 97.86 (97.51, 98.21) \\ 87.07 (80.25, 93.89) \\ 69.30 (61.62, 76.89) \\ 59.30 (61.62, 76.89) \\ 59.30 (61.62, 76.89) \\ 53.61 (80, 76.99, 89.7) \\ 73.67 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.76 (13.66, 3.86) \\ 3.6 (13.66, 3.8$	
biaktotal (195%, C)) devogranity, Tau' = 384, fest for overall effect. Z = 7 1.5 Zinc biajkota 2016 biozkart 2013 torokas 2200 anglani 2007 statistical (195%, C)) deterogranity, Tau' = 1133 fest for overall effect. Z = 1 biajkota 2016 biosede 2012 biosede	2.20; Chi ^{ij} 97.86 87.07 69.3 87.07 97.85 87.07 99.35.18 3.99; Chi ^{ij} 1.86 (P < 3.76 3.22.66 3.376 3.22.66 3.34 (P < 5.34 (P < 0.48 0.46 1.11 72.8 112.33 83; Chi ² + 112.33 83; Ch ² + 10.71 (P -	2 = 5.00, 0.00001 0.18 3.48 3.92 5.96 0.28 2.24 = 847.7 0.00001 0.05 0.28 2.93 8.58, df 0.00001 0.02 0.12 7.69, df 3.9.17 0.0000 0.24 3.9.17 0.00001 0.24 3.9.17 0.00001 0.24 3.9.17 0.00001 0.24 0.012 0.24 0.00001 0.02	$ \begin{array}{c} 0.1\%\\ 0.1\%$	$\begin{array}{l} 392.60 (342.33, 442.67) \\ 446.68 (250.83, 442.63) \\ 97.86 (97.51, 96.21) \\ 87.07 (80.225, 93.89) \\ 69.30 (61.62, 76.89) \\ 59.30 (61.62, 76.89) \\ 59.30 (61.62, 76.89) \\ 53.61 (61.07, 93.95.7) \\ 73.67 (43.96, 103.36) \\ 35.76 (3.66, 3.86) \\ 3.00 (24.3, 35.7) \\ 22.60 (16.86, 28.34) \\ 4.99 (1.66, 6.33) \\ 22.60 (16.86, 28.34) \\ 4.99 (1.66, 6.33) \\ 4.99 (1.66, 6.33) \\ 0.0001); P = 96\% \end{array}$	
Liebotal (1955; C) Liebrognenity: Tau' = 394,4 est for overall effect: Z = 7 1.5 Zinc loojko 2016 lo	2.2.0; Chi ² l 97.86 87.07 69.3 79 35.18 8.86 (P < 3.76 3.39; Chi ² = 4 22.6 3.76 3.39; Chi ² = 4 2.2.6 3.34 (P < 0.48 0.46 1.1 1; Chi ² = 2 11.37 (P - 72.88 3; Chi ² = 1 11.233 83; Chi ² = 1 10.71 (P -	Single Control (Control (Contro) (Control (Contro) (Contro) (Contro) (Contro) (C	$\begin{array}{c} 0.1\%\\ 0.1\%$	$\begin{array}{l} 392.60 (342.33, 442.87)\\ 446.88 (220.83, 442.87)\\ = 0.03); P=80\%\\ \end{array}\\ \begin{array}{l} 97.86 (97.51, 96.21)\\ 87.07 (80.225, 93.86)\\ (9.30) (87.32, 90.68)\\ 59.30 (61.62, 76.88)\\ 59.30 (61.62, 76.88)\\ 35.18 (30.77, 93.95.7)\\ 73.67 (43.98, 103.36)\\ 3.51 (83.07, 93.95.7)\\ 73.67 (43.98, 103.36)\\ 3.50 (22.45, 3.55)\\ 3.26 (16.86, 28.34)\\ 0.46 (0.42, 0.50)\\ 1.10 (0.86, 1.34)\\ 0.46 (0.42, 0.50)\\ 1.10 (0.86, 1.34)\\ 1.10 (0.86, 1.34)\\ 1.10 (0.86, 1.34)\\ 1.13 (0.86, 5.43)\\ 0.00001); P=95\%\\ \end{array}$	
bubbble (95% C)) deterogramity: Tau' = 34/4 deterogramity: Tau' = 34/4 deterogramity: Tau' = 34/4 deterogramity: Tau' = 13/3 deterogramity: Tau' = 113/2 deterogramity: Tau' = 113/2 deterogramity: Tau' = 113/2 deterogramity: Tau' = 113/2 deterogramity: Tau' = 13/2 deterogramity: Tau' = 13/2 deterogramity: Tau' = 13/2 deterogramity: Tau' = 13/2 detorokes 2020 tubbtal (95% C) deterogramity: Tau' = 10/2 detorokes 7/2 detorokes 2020 tubbtal (95% C) deterogramity: Tau' = 10/2 detorokes 7/2 detorokes 2020 tubbtal (95% C) detorokes 7/2 detorokes 7/2 det	2.2.0; Chi ² l 97.86 87.07 69.3 79 35.18 8.86 (P < 3.76 3.39; Chi ² = 4 22.6 3.76 3.39; Chi ² = 4 2.2.6 3.34 (P < 0.48 0.46 1.1 1; Chi ² = 2 11.37 (P - 92.71 72.8 83; Chi ² = 1 11.233 83; Chi ² = 1 10.71 (P -	Single Control (Control (Contro) (Control (Contro) (Contro) (Contro) (Contro) (C	$\begin{array}{c} 0.1\%\\ 0.1\%$	$\begin{array}{l} 392.60 (342.33, 442.87) \\ 446.88 (250.84), 442.83) \\ = 0.03); P = 80\% \\ \end{array} \\ \begin{array}{l} 97.86 (97.51, 96.21) \\ 87.07 (80.225, 93.86) \\ (9.3) (9.16, 27.638) \\ (9.3) (9.16, 27.638) \\ (9.3) (9.16, 27.638) \\ (3.5, 18) (30.7, 93.87) \\ 73.67 (343.86, 103.36) \\ (3.5, 18) (30.7, 93.87) \\ 73.67 (343.86, 103.36) \\ (3.5, 18) (30.7, 93.87) \\ 73.67 (343.86, 103.36) \\ (3.5, 18) (3.7, 93.87) \\ (3.5, 18) (3.6, 3.86) \\ (3.5, 10) (2.45, 3.55) \\ (3.5, 10) (2.45, 3.55) \\ (3.5, 10) (2.45, 3.55) \\ (3.5, 10) (2.45, 3.55) \\ (3.5, 10) (2.45, 3.55) \\ (3.5, 10) (2.45, 3.55) \\ (3.5, 10) (2.45, 3.55) \\ (3.5, 10) (2.45, 3.55) \\ (3.5, 10) (2.45, 3.55) \\ (3.5, 10) (2.45, 3.55) \\ (3.5, 10) (2.45, 3.55) \\ (3.5, 10) (3.5, 10) \\ (3.5, 10) \\ (3.5, 10) (3.5, 10) \\ (3.5, 10) \\$	
bubbble (95% C)) deterogramity: Tau" = 344, deterogramity: Tau" = 304, deterogramity: Tau" = 304, 1.13 Jane 1.13 Valanti 1.13 Capati 1.13 Valanti 1.13 Capati 1.13 Valanti 1.13 Capati 1.13	2.20, Chi ² 7.09 (P < 97.86 87.07 93.55,18 8.86 (P < 3.76 3.76 3.22.6 3.34 (P < 3.34 (P < 3.34 (P < 4.11 11.37 (P - 92.71 17.28 83; Chi ² = 4 112.33 83; Chi ² = 4 112.33 112.33 83; Chi ² = 5 112.33 112	0.18 3.48 3.92 5.96 2.24 0.05 0.28 2.93 0.0001 0.05 0.28 2.93 8.58, df 0.00001 0.02 0.12 7.69, df < 0.0000 0.22 7.69, df < 0.0000 0.22 7.69, df < 0.0000 0.22 3.93 9.17	$ \begin{array}{c} 0.1\%\\ 0.1\%$	$\begin{split} & 392.60 (342.33, 442.67) \\ & 446.68 (220.83, 442.53) \\ & = 0.03); P = 80\% \\ & 97.86 (97.51, 96.21) \\ & 87.07 (80.225, 93.89) \\ & 69.30 (61.62, 76.89) \\ & 69.30 (61.62, 76.89) \\ & 53.00 (67.32, 90.68) \\ & 3.51 (810.75, 93.857) \\ & 73.67 (43.86, 103.36) \\ & 3.57 (136.5, 3.86) \\ & 3.57 (136.5, 3.86) \\ & 3.57 (136.5, 3.86) \\ & 3.57 (136.5, 3.86) \\ & 3.57 (136.5, 3.86) \\ & 3.57 (136.5, 3.86) \\ & 3.50 (14.6, 6.33) \\ & 0.00001); P = 90\% \\ \hline & 0.00001); P = 96\% \\ \hline & 0.000010; P = 96\% \\ & 20.47 (182.24, 93.18) \\ & 72.80 (65.92, 78.68) \\ & 92.71 (92.24, 93.18) \\ & 72.80 (65.92, 78.68) \\ & 112.33 (143.6, 103.30) \\ & 90.67 (74.07, 107.26) \\ & 20.00001); P = 96\% \\ \hline & 20.47 (18.88, 22.07) \\ & 47 (P < 0.00001); P = 99.7\% \\ \hline \end{pmatrix}$	tion to for the second
bubbale (BS% C) letterogramity: Tau" = 344, est of coveral effect. Z = 7 1.1.5 Zine diaglos 2016 totopics 2016 totopics 2010 totopics 2010 totopics 2020 tubbale (BS% C) teterogramity: Tau" = 1.87 est for overal fields; 1.1.5 Valuation (C) teterogramity: Tau" = 1.87 est for overal fields; 1.1.5 Valuation (C) tubbale (BS% C) teterogramity: Tau" = 1.87 est for overal fields; 1.1.5 Selamiting tubbale (BS% C) teterogramity: Tau" = 0.01 est for overal infect. Z = 1 1.1.5 Copper (Saw 2200 tubbale (BS% C) teterogramity: Tau" = 0.01 est for overall effect. Z = 1 1.1.5 Copper (Saw 2200 tubbale (BS% C) teterogramity: Tau" = 0.01 est for overall effect. Z = 1 -0.01 est for overall effe	220, Chi ² hi 7.09 (P < 97.86 87.07 69.3 79 35.18 3.09, Chi ² + 3.39, Chi ² + 3.39, Chi ² + 3.39, Chi ² + 3.30, Chi ² + 1.1,37 (P / 92,71 1,37 (P / 92,71) 1,37 (P / 92,71 1,37 (P / 92,71) 1,37 (P / 92,71) 1,3	= 5.00, 0.00001 0.18 3.49 3.92 2.24 = 847.7. 0.00001 0.28 2.93 8.58, df 0.00001 0.22 2.93 8.58, df 0.00001 0.24 3.9. 7.69, df (-0.0000 0.24 3.9. 9.17 = 84.40, < 0.0000 531434, < 0.00000 531434, < 0.000000 531434, < 0.00000 531434, < 0.000000 531434, < 0.000000 531434, < 0.000000 531434, < 0.000000 531434, < 0.000000 531434, < 0.000000 531434, < 0.000000 531434, < 0.000000 531434,	$ \begin{array}{c} 0.1\%\\ 0.1\%$	$\begin{split} & 392.60 (342.33, 442.67) \\ & 446.68 (220.83, 442.53) \\ & = 0.03); P = 80\% \\ & 97.86 (97.51, 96.21) \\ & 87.07 (80.225, 93.89) \\ & 69.30 (61.62, 76.89) \\ & 69.30 (61.62, 76.89) \\ & 53.00 (67.32, 90.68) \\ & 3.51 (810.75, 93.857) \\ & 73.67 (43.86, 103.36) \\ & 3.57 (136.5, 3.86) \\ & 3.57 (136.5, 3.86) \\ & 3.57 (136.5, 3.86) \\ & 3.57 (136.5, 3.86) \\ & 3.57 (136.5, 3.86) \\ & 3.57 (136.5, 3.86) \\ & 3.50 (14.6, 6.33) \\ & 0.00001); P = 90\% \\ \hline & 0.00001); P = 96\% \\ \hline & 0.000010; P = 96\% \\ & 20.47 (182.24, 93.18) \\ & 72.80 (65.92, 78.68) \\ & 92.71 (92.24, 93.18) \\ & 72.80 (65.92, 78.68) \\ & 112.33 (143.6, 103.30) \\ & 90.67 (74.07, 107.26) \\ & 20.00001); P = 96\% \\ \hline & 20.47 (18.88, 22.07) \\ & 47 (P < 0.00001); P = 99.7\% \\ \hline \end{pmatrix}$	patients. Forest plot of

The sensitivity analysis by removing two studies (Swain et al. and Yarahmadi et al.) (30, 34) with the lowest risk assessment scores, does not alter the original results (mean = 20.53, 95% CI: 18.90, 22.15). The result of the sensitivity analysis is depicted in Figure 5.

The apparent asymmetry in the funnel plot (Figure 6) suggests possible publication bias.

4 Discussion

Identifying and managing chronic wounds is a critical healthcare objective. DFU generally starts with minor injuries that go unnoticed because of diabetic neuropathy (altered sensitivity and nerve damage). Convergence of immunological, vascular, nutritional, glycaemic, and infectious conditions influences

16.80 [10.27, 23.33] 7.90 [6.27, 9.53] 25.41 [-9.61, 60.43] 16.86 [13.55, 20.17] 17.70 [14.37, 21.03] 12.40 [10.69, 11.11] 26.20 [10.69, 21.03] 16.8 7.9 25.41 16.86 17.7 12.4 25.3 3.33 0.83 17.87 1.69 1.7 0.87 3.54 3.5% 5.1% 0.3% 4.6% 5.0% art 2019 ahmadi 2021 Motal (95% d 25.30 0.87 ity: Ta 4.1.2 Europe 11.8 22.04 12.4 11.87 17.9 1.11 1.5 1.07 4.9% 4.7% 5.0% 5.1% 4.9% 24.6% 11.80 [9.62, 10.65 22.04 [19.10, 24.98 12.40 [10.30, 14.56 11.87 [10.65, 13.09 17.90 [15.61, 20.19 15.07 [11.67, 18.47 Maggi 2014 0.62 Tsitsou 2020 Subtotal (95% CI) foot for our 1 3 Asial Pacific 14.35 [15.22 11.21 [9.00 24.85 [21.89 14.25 [11.90 19.50 [16.85 14.81 [12.99 16.13 [13.44 16.11 [13.21 14.81 [13.91 11.21 24.85 14.25 19.5 14.81 16.13 16.11 14.81 8.23 1.13 1.51 1.2 1.35 0.93 1.37 1.48 0.46 0.12 Dai 2020 4.9% 4.7% 4.8% 5.0% 4.8% 4.7% 5.2% 5.2% 48.9% E14 04 Total (95% CI) 100.0% 15.55 [13.44, 17.65] в 1.1 Min m, 95% Cl 95% CI SE Weight IV. F IV. R 87.07 3.48 20.0% 79 5.96 19.6% 87.07 [80.25, 93.89 2013 19.6% 39.6% 79.00 [67.32, 90.68] 84.49 [77.11, 91.87] • % CI) = 1.37, df = 1 (F = 0.24); |2 = 279 6.1.2 Asia/ Pacifi Yadav 2020 Subtotal (95% CI) 69.30 [61.62, 76.98] 35.18 [30.79, 39.57] 52.09 [18.65, 85.52] 69.3 3.92 20.0% 35.18 2.24 20.1% 40.1% Heterogeneity: 1 Test for overall 6.1.3 Africa 97.86 0.18 20.2% 97.86 [97.51, 98.21] 20.2% 97.86 [97.51, 98.21] Bolajoko 2016 Subtotal (95% CI) Heterogeneity: Not applicable Test for overall effect: Z = 543.67 (P < 0.00001) rotal (95% Cl) 100.0% 73.67 [43.98, 103.36] Heterogeneity. Tau" = 1133.99; Chi² = 847.75, df = 4 (P < 0.00001); P Tost for overall offoct: Z = 4.86 (P < 0.00001) Tost for subgroup diffances = 0.00001 ct: Z = 4.86 (P < 0.00001) ifferences: Chi² = 19.78, df = 2 (P < 0.0001), i² = 89.9% С Mean Mear Study or Subgro 5.2.1 Europe SE Weight IV, Random, 95% CI IV. B m, 95% Cl 26.6% 25.5% 52.1% 9.54 [9.46, 9.62] 9.30 [9.12, 9.48] 9.43 [9.20, 9.67] 9.54 0.04 9.3 0.09 tal (95% CI) 0.01); 12 = 83% eity: Tau 5.2.2 Asia/ Pacific 0.12 24.5% 0.15 23.4% 47.9% Swain 2012 Subtotal (9 8.53 [8.24, 8.82] 8.75 [8.33, 9.18] 5% CI) 0.03): 12 = 80% hity: Tau² = 0 erall effect: 2 FIGURE 4 Subgroup analysis based on geographic location was assessed for vitamin D, zinc, and calcium. (A) Mean vitamin D levels across Middle East, Europe, and Asia/Pacific regions, (B) Mean zinc levels across Middle East, Asia/Pacific, and African regions. (C) Mean calcium levels across Europe and Asia/Pacific regions.

ndom. 95% Cl

SE

Study or Subgro 4.1.1 Middle Eas


wound healing. The present meta-analysis has revealed significantly lower circulating levels of vitamin D, vitamin C, magnesium, and selenium among patients with DFU than in control groups. However, other micronutrients did not differ significantly between DFU patients and controls.

Nutritional deficiencies impede normal stages of wound healing, a complex four-step process involving hemostasis,

tudy or Subgroup	Mean	SE	Weight	Mean IV, Random, 95% Cl	Mean IV, Random, 95% Cl
1.1 Vitamin D	40.5			40.00 /40.07.00.001	_
farideh 2016 rookes 2020	16.8 18.55	3.33	1.8% 2.3%	16.80 [10.27, 23.33] 18.55 [15.22, 21.88]	
aglar 2018	7.9	0.83	2.5%	7.90 [6.27, 9.53]	
ai 2020	11.21	1.13	2.4%	11.21 [9.00, 13.42]	-
arlington 2019	24.85	1.51	2.3%	24.85 [21.89, 27.81]	
eldkamp 2018 upta 2016	11.8 14.25	1.11 1.2	2.4%	11.80 [9.62, 13.98] 14.25 [11.90, 16.60]	
alschou-Jensen 2021	22.04	1.5	2.4%	22.04 [19.10, 24.98]	-
amble 2020	19.5	1.35	2.4%	19.50 [16.85, 22.15]	7
aggi 2014	12.4	1.07	2.4%	12.40 [10.30, 14.50]	-
ozaffari-Khosravi 2016 ajafpour 2019	25.41 16.86	17.87 1.69	0.2% 2.3%	25.41 [-9.61, 60.43] 16.86 [13.55, 20.17]	
azzaghi 2017	17.7	1.7	2.3%	17.70 [14.37, 21.03]	-
mart 2019	12.4	0.87	2.5%	12.40 [10.69, 14.11]	•
wain 2012 wari 2013	14.81 16.13	0.93	2.4%	Not estimable 16.13 [13.44, 18.82]	-
wari 2014	16.13	1.48	2.4%	16.11 [13.21, 19.01]	-
odorova 2020	11.87	0.62	2.5%	11.87 [10.65, 13.09]	1 E
sitsou 2020	17.9	1.17	2.4%	17.90 [15.61, 20.19]	
iao 2020 arahmadi 2021	14.81 25.3	0.46	2.5%	14.81 [13.91, 15.71] Not estimable	
ubair 2013	8.23	0.12	2.5%	8.23 [7.99, 8.47]	
ubtotal (95% CI)			45.5%	15.23 [13.04, 17.42]	•
eterogeneity: Tau ² = 21.9 est for overall effect: Z = 1	7; Chi ² = 3.62 (P ·	702.97, < 0.0000	df = 19 (F)1)	° < 0.00001); I² = 97%	
1.2 Magnesium					
fzali 2019	1.53	0.02	2.5%	1.53 [1.49, 1.57]	t
ozkurt 2013 eskek 2013	1.15 1.73	0.04	2.5%	1.15 [1.07, 1.23] 1.73 [1.67, 1.79]	[.
oran 2001	1.48	0.05	2.5%	1.48 [1.36, 1.60]	ŀ
azzaghi 2018	2.05	0.03	2.5%	2.05 [1.99, 2.11]	•
adav 2020 ubtotal (95% CI)	1.23	0.06	2.5% 15.3%	1.23 [1.11, 1.35] 1.53 [1.28, 1.78]	
eterogeneity: Tau ² = 0.10	$Chi^2 = 4$	24.16			
est for overall effect: Z = 1	1.94 (P	< 0.0000	01)		
1.3 Calcium					
haikh 2020	8.96	0.12	2.5%	8.96 [8.72, 9.20]	•
wain 2012	8.53 9.54	0.15	2.5%	8.53 [8.24, 8.82]	
odorova 2020 sitsou 2020	9.54	0.04	2.5%	9.54 [9.46, 9.62] 9.30 [9.12, 9.48]	
ubtotal (95% CI)			10.2%	9.10 [8.71, 9.49]	
leterogeneity: Tau ² = 0.15 est for overall effect: Z = 4	Chi ² = 6 5.34 (P ·	0.53, df < 0.0000	= 3 (P <))1)	0.00001); l² = 95%	
1.6 Vitamin B12 rookes 2020	294.6	35.52	0.1%	294.60 [224.98, 364.22]	,
ionz'alez 2010	392.6	25.65	0.1%	392.60 [342.33, 442.87]	•
ubtotal (95% CI) leterogeneity: Tau ² = 3842	20- Chi	- 5.00	0.2%	346.68 [250.83, 442.53]	
est for overall effect: Z = 7	.09 (P <	0.00001	ui = 1 (r I)	- 0.03), 1 - 00 %	
1.7 zinc					
olajoko 2016 ozkurt 2013	97.86 87.07	0.18	2.5% 1.8%	97.86 [97.51, 98.21] 87.07 [80.25, 93.89]	
rookes 2020	69.3	3.92	1.6%	69.30 [61.62, 76.98]	
arijani 2007	79	5.96	1.1%	79.00 [67.32, 90.68]	
adav 2020 ubtotal (95% CI)	35.18	2.24	2.1%	35.18 [30.79, 39.57] 73.67 [43.98, 103.36]	-
eterogeneity: Tau ² = 1133	00- Chi	= 847 7			
est for overall effect: Z = 4	.86 (P <	0.00001	l)	(· · · · · · · · · · · · · · · · · · ·	
1.8 Vitamin C			2.5%		
olajoko 2016 osede 2012	3.76	0.05	2.5% 2.5%	3.76 [3.66, 3.86] 3.00 [2.45, 3.55]	
rookes 2020	22.6	2.93	1.9%	22.60 [16.86, 28.34]	
ubtotal (95% CI)			7.0%	4.99 [3.16, 6.83]	•
eterogeneity: Tau ² = 1.87 ast for overall effect: Z = 5	Chi ² = 4 .34 (P <	8.58, df 0.00001	= 2 (P < 1	0.00001); l ² = 96%	
1.9 Selenium					
olajoko 2016	0.48	0.001	2.5%	0.48 [0.48, 0.48]	t
osede 2012 rookes 2020	0.46 1.1	0.02	2.5% 2.5%	0.46 [0.42, 0.50] 1.10 [0.86, 1.34]	
ubtotal (95% CI)			7.6%	0.54 [0.45, 0.64]	
eterogeneity: Tau ² = 0.01	Chi² = 2	7.69, df	= 2 (P <	0.00001); l² = 93%	
est for overall effect: Z = 1	1.37 (P	< 0.0000	01)		
.1.10 Copper olajoko 2016	92.71	0.24	2.5%	92.71 [92.24, 93.18]	
ozkurt 2013	72.8	3	1.9%	72.80 [66.92, 78.68]	-
adav 2020 ubtotal (95% CI)	112.33	9.17	0.6% 5.1%	112.33 [94.36, 130.30] 90.67 [74.07, 107.26]	
ubtotal (95% CI) eterogeneity: Tau ² = 189. est for overall effect: Z = 1	33; Chi ² :	= 48.40,	df = 2 (P	< 0.00001); l ² = 96%	
est for overall effect: Z = 1 otal (95% CI)	олт (Р ·	- 0.0000	100.0%	20.53 [18.90, 22.15]	•
leterogeneity: Tau ² = 27.0	2; Chi² =	531148	.81, df = 4	15 (P < 0.00001); I ² = 100%	-50 -25 0 25 50
est for overall effect: Z = 2 est for subgroup differenc	474 (P ·	< 0.0000	01)		-50 -25 0 25 50
	es: Unif :	- ZU96.(14, at = 7	(P < 0.00001), P = 99.7%	

performed by eliminating results of two studies with the lowest risk assessment scores.

inflammation, proliferation, and tissue remodelling (51). Chronic wounds generally get stalled at the inflammatory phase stage due to the continuous recruitment of neutrophils to the healing site, producing various alterations at systemic and molecular levels. Malnutrition also prolongs the inflammatory phase by decreasing fibroblast proliferation, and collagen formation, in addition to altering its tensile strength and angiogenesis. Malnutrition can increase the risk for infection by reducing T-cell function, phagocytic activity, complement, and antibody levels (52). Nutrients can aid wound healing by minimizing free radicals (neutrophils can release reactive oxygen species) and oxidative stress parameters by balancing the oxidant-antioxidant defenses



(53). The higher proportion of nutrient insufficiencies in DFU could disturb glycaemic control, which in turn delays wound healing (49).

Vitamin D is well known for its pleiotropy. Vitamin D deficiency (VDD) is associated with impaired beta-cell function, insulin resistance (54), and micro and macro-vascular complications of DM progression. A recent systematic review and meta-analysis of 1115 patients reported that severe VDD increased DFU risk by 3.2 times (55). Interestingly, Darlington et al. observed similar vitamin D levels between DM and DFU patients but with poor DFU outcomes (25). Pena et al. identified VDD to be dominantly prevalent (55.7%) among DFU patients (6). Dai et al. proposed vitamin D levels below 13.68 ng/ml as the threshold for DFU risk (37).

Vitamin D positively improves immunological, neurological, and vascular conditions associated with DFU. Vitamin D is also an immunomodulator that facilitates T and B cell activation by macrophages. Gupta B and Singh SK showed that macrophages treated with vitamin D3, *in vitro*, enhanced phagocytosis in DFU setting (26). Vitamin D inhibits T-helper cells-1 (Th1) that promote cell-mediated inflammatory response while stimulating Th2 cells that aid wound healing (56). Tiwari et al. suggest 10ng/ml of 25hydroxy vitamin D [25 (OH)D] as the threshold for immunological alterations in DM. Reports suggest that VDD is associated with an increased release of inflammatory cytokines (TNF- α , IL-1 β , IL-6) in DFU patients (48). Vitamin D induces the transcription of cathelicidin and defensins that aid in phagocytosis, thereby enhancing the antimicrobial innate immune system (57).

Asian DM patients with VDD are at 1.22 times greater risk for developing peripheral neuropathy than those with normal vitamin D levels (58). Basit et al. showed that 600,000 IU of vitamin D, over 20 weeks, offered significant pain relief in painful diabetic neuropathy (59). VDD may also be associated with increased sensitivity to pain (60). Swain et al. reported that nearly 52% of DFU patients with vascular calcification (VC) had severe VDD (30). Their subgroup analyses showed that the risk for VC was 2.4 times higher in patients with vitamin D levels < 10 ng/ml. Sugden et al. demonstrated that a single high dose of vitamin D supplementation can improve the flow-mediated vasodilation of the brachial artery by 2.3% (61).

Most studies have focused on the significant role of vitamin D in DFU compared to other nutrients. We need more clinical and molecular studies to explain the results. We identified four clinical trials that estimated 25 (OH) D levels and studied the effects of vitamin D supplementation on DFU outcomes. Kamble et al. and Razzaghi et al. investigated the effect of 60,000 IU and 50,000 IU of vitamin D, respectively, for 12 weeks, in DFU healing (18, 21) and reported that supplements improved wound healing and biochemical parameters. Halschou-Jensen et al. showed that two daily doses (170 μ g and 20 μ g) of vitamin D supplements in chronic DFU (17) delivered a median ulcer reduction of 100% (high dose) and 57% (low dose). Mozaffari-Khosravi et al. demonstrated that a single dose of 300,000 IU of vitamin D improved DFU outcomes compared to 150,000 IU (22).

Magnesium is an essential element with a pivotal role in human physiology, especially as a cofactor for enzymatic and metabolic pathways (62). Magnesium, essential for collagen formation and tissue development, is altered in DM (63). Hypomagnesemia in DM could result from enhanced renal excretion associated with insulin resistance, glycosuria, and hyperglycemia. Diabetic autonomic neuropathy alters intestinal absorption (27) and reduces dietary intake of magnesium. Improving insulin metabolism can potentially delay vascular complications in DFU. Magnesium plays a role in the formation of malonyl-COA and inhibits voltage-dependent calcium channels that facilitate insulin secretion (20). Hypomagnesemia has been associated with abnormal platelet activity and can induce a proinflammatory response that activates systemic inflammation (64). Hypomagnesemia has also been linked with neuronal damage and diabetic peripheral neuropathy in DM patients (65, 66). Further magnesium supplementation was found to promote peripheral nerve regeneration (67).

Yadav et al. observed an inverse relationship between DM duration and serum magnesium, copper, and zinc levels (49). Rodrigues-Moran et al. provided the first evidence for hypomagnesemia as a risk factor for DFU (OR: 2.9, 95% CI: 1.7-6.8; P = 0.01) (46). Interestingly, Moon et al. have reported that hypermagnesemia is a risk factor for amputation in hospitalized DFU patients (OR:2.480; P = 0.043), which could be attributed to the association between renal disorder and hypermagnesemia (68).

Two studies have investigated the role of magnesium supplementation in DFU patients. Razzaghi et al. found that 250 mg of magnesium for 12 weeks improved the ulcer area, glycaemic parameters, and other antioxidant and anti-inflammatory parameters (20). Afzali et al. showed that 250mg magnesium plus 400 IU vitamin E can improve ulcer area, glycaemic parameters, lipid profile, and other antioxidant and anti-inflammatory parameters (16). Coger et al. have suggested magnesium supplements during the late-inflammatory and mid-proliferative phases (69).

A population-based cohort study (25,639 participants; 8-12 years) demonstrated an inverse association between vitamin C

levels and incidence of DM (70). Vitamin C is a strong antioxidant, a vital co-factor in several enzymatic reactions, and promotes anti-inflammatory and pro-resolution effects in macrophages, together alleviating pro-inflammatory responses (71). Vitamin C deficiency in DM has been established, and its impact on serum malondialdehyde suggests increased oxidative stress, aggravating micro- and macro-vascular complications in DM (72).

A meta-analysis of RCTs shows that vitamin C supplements significantly improved endothelial function in DM. Vitamin C is a direct antioxidant that scavenges reactive oxygen species and enhances the bioavailability of nitric oxide (NO) (73). In 2021, an RCT (n= 16) of vitamin C supplements showed benefits on foot ulcers (74). Inadequate vitamin C supplements can cause stagnation in the proliferative and maturation phases of wound healing, thereby prolonging wound healing time (71). Vitamin C facilitates the synthesis and cross-linking of collagen, enhancing vascular integrity and capillary bed strength (75). Pena et al. identified 73% of DFU patients with suboptimal levels of vitamin C (6). An RCT by Yarahmadi et al. showed that a combination of platelet-rich plasma, fibrin glue dressing, and vitamins E and C improved wound healing of DFU by alleviating oxidative stress (76).

Dixit et al. reported a significant difference between selenium levels in patients with chronic non-healing wounds and HC (77). An *in vivo* study on diabetic mice demonstrated an antioxidant role for selenium (restoring normal antioxidant status), and as an insulin mimetic in normalizing glucose levels. Selenium can also downregulate connexin expression, which promotes anti-inflammatory and anti-apoptotic signals, in addition to enhancing angiogenesis (78). Macrophages treated with selenium promote peroxisome proliferator-activated receptor (PPAR)- γ - dependent switch from M1 to M2 phenotype in the presence of IL-4 (79), suggesting selenium's wound healing potential.

Currently, available evidence suggests that immune-endocrine effects and antioxidant properties of selenium benefit infections in DM (80). Although we did not identify any interventional studies on the effect of selenium in DFU, selenium levels were markedly different in DFU patients *vis-a-vis* HC and DM (35, 41, 42).

The strength of the current study: This is the first systematic review with meta-analysis comparing micronutrient status in DFU between HC and DM. The limitations are First: relatively small sample size in some studies. Second: most study designs were retrospective or crosssectional, limiting the possibility of establishing a causal relationship between the micronutrients and DFU. Third: marked publication bias was observed. Fourth: cannot rule out the possibility of ecology and environment as confounders. Nevertheless, the existing challenge is to articulate the effect of these supplementations in the patient population as the number of well-designed RCT's are few.

We have observed a significant association between DFU and vitamin D, vitamin C, magnesium, copper, and selenium levels. Although other micronutrients also influence multiple phases of wound healing, we did not observe a significant association. Nevertheless, we recommend assessing micronutrient levels in DFU patients and investigating their pathological correlation. Future investigations should address the effect of specific micronutrients in DFU management, molecular mechanisms of action of micronutrients, as well as nutrigenomic studies that reveal gene-nutrient interaction and its possible effects on DFU healing. Individual genetic variants could respond differently to micronutrients, and thus directly or indirectly influence the prevention and management of DFU. Nutrigenomic approaches would deliver a holistic and personalized approach to the management of DFU.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Author contributions

SK and SM formulated the research question and designed the study. SK, TB, RB, and SM were involved in carrying out the study, analyzing the data, and interpreting the findings. SK and SM wrote the manuscript. MU, MM, KS, GR, MR, and AK, critically evaluated the manuscript. All authors contributed to the article and approved the submitted version.

Acknowledgments

SK is grateful to Indian Council of Medical Research (ICMR), New Delhi for the award of Senior Research Fellowship [No. 3/1/3 (16)/Endo-fellowship/21-NCD-III]. The authors thank the Manipal Academy of Higher Education for providing support and resources.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

 Sargen MR, Hoffstad O, Margolis DJ. Geographic variation in Medicare spending and mortality for diabetic patients with foot ulcers and amputations. J Diabetes Complications (2013) 27:128–33. doi: 10.1016/j.jdiacomp.2012.09.003

2. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med (2017) 376:2367-75. doi: 10.1056/NEJMra1615439

3. Zhang P, Lu J, Jing Y, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis. *Ann Med* (2017) 49:106–16. doi: 10.1080/07853890.2016.1231932

4. Brennan MB, Hess TM, Bartle B, Cooper JM, Kang J, Huang ES, et al. Diabetic foot ulcer severity predicts mortality among veterans with type 2 diabetes. *J Diabetes Complications* (2017) 31:556–61. doi: 10.1016/j.jdiacomp.2016.11.020

5. Hobizal KB, Wukich DK. Diabetic foot infections: current concept review. *Diabetes Foot Ankle* (2012) 2012:3. doi: 10.3402/dfa.v3i0.18409

6. Pena G, Kuang B, Cowled P, Howell S, Dawson J, Philpot R, et al. Micronutrient status in diabetic patients with foot ulcers. *Adv Wound Care New Rochelle* (2019) 9:9–15. doi: 10.1089/wound.2019.0973

7. Yazdanpanah L, Nasiri M, Adarvishi S. Literature review on the management of diabetic foot ulcer. *World J Diabetes* (2015) 6:37–53. doi: 10.4239/wjd.v6.i1.37

8. Ghaly P, Iliopoulos J, Ahmad M. The role of nutrition in wound healing: an overview. Br J Nurs (2021) 30:S38-42. doi: 10.12968/bjon.2021.30.5.S38

9. Valdés-Ramos R, Ana Laura G-L, Beatriz Elina M-C, Alejandra Donaji B-A. Vitamins and type 2 diabetes mellitus. *Endocr Metab Immune Disord Drug Targets* (2015) 15:54–63. doi: 10.2174/1871530314666141111103217

10. Available at: https://unitslab.com/ (Accessed 05 February 2022). unitslab.com.

11. Department of Obstetrics or Gynaecology. *StatTools: Combine means and SDs into one group program*. Available at: http://www.obg.cuhk.edu.hk/ResearchSupport/StatTools/CombineMeansSDs_Pgm.php (Accessed 05 February 2022).

12. Higgins JP, Li T, Deeks JJ. Chapter 6: Choosing effect measures and computing estimates of effect, in: *Cochrane handbook for systematic reviews of interventions* (2019). Available at: https://training.cochrane.org/handbook/current/chapter-06 (Accessed 02 January 2022).

13. Momen-Heravi M, Barahimi E, Razzaghi R, Bahmani F, Gilasi HR, Asemi Z. The effects of zinc supplementation on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial. *Wound Repair Regen* (2017) 25:512–20. doi: 10.1111/wrr.12537

14. Qasim SM, Ra'ad Al-dorri AZ, Mahmood Al-Izzi MH. The relationship between vitamin d deficiency and interleukins 8 and 10 in diabetes mellitus. *SRP* (2020) 11:149–55. doi: 10.31838/srp.2020.9.26

15. Greenhagen RM, Frykberg RG, Wukich DK. Serum vitamin d and diabetic foot complications. *Diabetes Foot Ankle* (2019) 10:1579631. doi: 10.1080/2000625X.2019.1579631

16. Afzali H, Jafari Kashi AH, Momen-Heravi M, Razzaghi R, Amirani E, Bahmani F, et al. The effects of magnesium and vitamin e co-supplementation on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial. *Wound Repair Regen* (2019) 27:277–84. doi: 10.1111/wrr.12701

17. Halschou-Jensen PM, Sauer J, Bouchelouche P, Fabrin J, Brorson S, Ohrt-Nissen S. Improved healing of diabetic foot ulcers after high-dose vitamin d: A randomized double-blinded clinical trial. *Int J Low Extrem Wounds* (2021), 1–9. doi: 10.1177/15347346211020268

18. Kamble A, Ambad RS, Padamwar M, Kakade A, Yeola M. To study the effect of oral vitamin d supplements on wound healing in patient with diabetic foot ulcer and its effect on lipid metabolism. *Int J Res Pharm Sci* (2020) 11:2701–6. doi: 10.26452/ ijrps.v11i2.2290

19. Maggi S, Siviero P, Brocco E, Albertin M, Romanato G, Crepaldi G. Vitamin d deficiency, serum leptin and osteoprotegerin levels in older diabetic patients: An input to new research avenues. *Acta Diabetol* (2014) 51:461–9. doi: 10.1007/s00592-013-0540-4

20. Razzaghi R, Pidar F, Momen-Heravi M, Bahmani F, Akbari H, Asemi Z. Magnesium supplementation and the effects on wound healing and metabolic status in patients with diabetic foot ulcer: a randomized, double-blind, placebo-controlled trial. *Biol Tra Elem Res* (2018) 181:207–15. doi: 10.1007/s12011-017-1056-5

21. Razzaghi R, Pourbagheri H, Momen-Heravi M, Bahmani F, Shadi J, Soleimani Z, et al. The effects of vitamin d supplementation on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial. *J Diabetes Complications* (2017) 31:766–72. doi: 10.1016/j.jdiacomp.2016.06.017

22. Mozaffari-Khosravi H, Haratian-Arab M, Tavakkoli HM, Nadjarzadeh A. Comparative effect of two different doses of vitamin d on diabetic foot ulcer and inflammatory indices among the type 2 diabetic patients: a randomized clinical trial. *Iran J Diabetes Obes* (2016) 8:164–71.

23. Palacka P, Kucharska J, Murin J, Dostalova K, Okkelova A, Cizova M, et al. Complementary therapy in diabetic patients with chronic complications: A pilot study. *Bratisl Lek Listy* (2010) 111:205–11.

24. Afarideh M, Ghanbari P, Noshad S, Ghajar A, Nakhjavani M, Esteghamati A. Raised serum 25-hydroxyvitamin d levels in patients with active diabetic foot ulcers. *Br J Nutr* (2016) 115:1938–46. doi: 10.1017/S0007114516001094

25. Darlington CJD, Kumar SS, Jagdish S, Sridhar MG. Evaluation of serum vitamin d levels in diabetic foot infections: A cross-sectional study in a tertiary care center in south India. *Iran J Med Sci* (2019) 44:474–82. doi: 10.30476/ijms.2018.44951

26. Gupta B, Singh SK. Invitro study of role of vitamin d on macrophages dysfunction in patients with diabetic foot infection. *Int J Adv Res* (2016) 4:1633–7. doi: 10.21474/IJAR01/753

27. Keşkek SO, Kırım S, Karaca A, Saler T. Low serum magnesium levels and diabetic foot ulcers. *Pak J Med Sci* (2013) 29:1329–33. doi: 10.12669/pjms.296.3978

28. Shaikh IA, Masood N, Shaikh FA, Shaikh MA. Diabetic foot ulcers: Correlation of nutritional status of type 2 diabetic patients of Hyderabad sindh, Pakistan. *TPMJ* (2017) 24:707–12. doi: 10.17957/TPMJ/17.3869

29. Smart H, AlGhareeb AM, Smart SA. 25-hydroxyvitamin d deficiency: Impacting deep-wound infection and poor healing outcomes in patients with diabetes. *Adv Skin Wound Care* (2019) 32:321-8. doi: 10.1097/01.ASW.0000559614.90819.45

30. Swain J, Tiwari S, Pratyush D, Dwivedi A, Gupta B, Shukla RC, et al. Vascular calcification in diabetic foot and its association with calcium homeostasis. *Indian J Endocrinol Metab* (2012) 16, Suppl 2:S450–2. doi: 10.4103/2230-8210.104128

31. Todorova AS, Jude EB, Dimova RB, Chakarova NY, Serdarova MS, Grozeva GG, et al. Vitamin d status in a Bulgarian population with type 2 diabetes and diabetic foot ulcers. *Int J Low Extrem Wounds* (2022) 21:506–12. doi: 10.1177/1534734620965820

32. Tsitsou S, Dimosthenopoulos C, Eleftheriadou I, Andrianesis V, Tentolouris N. Evaluation of vitamin d levels in patients with diabetic foot ulcers. *Int J Low Extrem Wounds* (2023) 22:27–35. doi: 10.1177/1534734620984584

33. Xiao Y, Wei L, Xiong X, Yang M, Sun L. Association between vitamin d status and diabetic complications in patients with type 2 diabetes mellitus: A cross-sectional study in hunan China. *Front Endocrinol (Lausanne)* (2020) 11:564738. doi: 10.3389/ fendo.2020.564738

34. Yarahmadi A, Mostafavi-Pour Z, Saeed MH, Azarpira N, Mousavian A, Bonakdaran S, et al. Association between serum vitamin d, hs-CRP, and prooxidantantioxidant balance with anthropometric and biochemical parameters in patients with diabetic foot ulcers. *Clin Diabetol* (2021) 10:138–43. doi: 10.5603/DK.2020.0064

35. Brookes JDL, Jaya JS, Tran H, Vaska A, Werner-Gibbings K, D'Mello AC, et al. Broad-ranging nutritional deficiencies predict amputation in diabetic foot ulcers. *Int J Low Extrem Wounds* (2020) 19:27–33. doi: 10.1177/1534734619876779

36. Caglar S, Caglar A, Pilten S, Albay G, Beytemur O, Sari H. Osteoprotegerin and 25-hydroxy vitamin d levels in patients with diabetic foot. *Eklem Hastalik Cerrahisi* (2018) 29:170–5. doi: 10.5606/ehc.2018.60797

37. Dai J, Yu M, Chen H, Chai Y. Association between serum 25-OH-Vitamin d and diabetic foot ulcer in patients with type 2 diabetes. *Front Nutr* (2020) 7:109. doi: 10.3389/fnut.2020.00109

38. Feldkamp J, Jungheim K, Schott M, Jacobs B, Roden M. Severe vitamin D3 deficiency in the majority of patients with diabetic foot ulcers. *Horm Metal Res* (2018) 50:615–9. doi: 10.1055/a-0648-8178

39. Najafipour F, Aghamohammadza N, Zonouz NR, Houshyar J. Role of serum vitamin d level in progression of diabetic foot ulcer. *JCDR* (2019) 13:15–7. doi: 10.7860/ JCDR/2019/39974.12689

40. Zubair M, Malik A, Meerza D, Ahmad J. 25-hydroxyvitamin d [25(OH)D] levels and diabetic foot ulcer: Is there any relationship? *Diabetes* (2013) 7:148–53. doi: 10.1016/j.dsx.2013.06.008

41. Bolajokol EB, Akinosui OM, Anetor JI, Mossanda KS. Micronutrient status and its effect on glycaemic indices in type 2 diabetics with foot ulcer in ibadan, Nigeria. *Afr J Med Med Sci* (2016) 45:83–90.

42. Bosede BE, Olubayo A, John A, Adesoji F, Aduragbemi A, Ayodele I, et al. Ameliorative role of antioxidant micronutrients: Selenium, vitamins c and e on oxidative stress and wound healing in type 2 diabetic patients with foot ulcer in ibadan. *IIOAB J* (2012) 3:1–5.

43. Bozkurt F, Tekin R, Gulsun S, Satici O, Deveci O, Hosoglu S. The levels of copper, zinc and magnesium in type II diabetic patients complicated with foot infections. *Int J Diabetes Dev Ctries* (2013) 33:165–9. doi: 10.1007/s13410-013-0130-6

44. González R, Pedro T, Real JT, Martínez-Hervás S, Abellán MR, Lorente R, et al. Plasma homocysteine levels are associated with ulceration of the foot in patients with type 2 diabetes mellitus. *Diabetes Metab Res Rev* (2010) 26:115–20. doi: 10.1002/dmrr.1061

45. Larijani B, Shooshtarizadeh P, Mosaffa N, Heshmat R. Polymorphonuclear leucocyte respiratory burst activity correlates with serum zinc level in type 2 diabetic patients with foot ulcers. *Br J BioMed Sci* (2007) 64:13–7. doi: 10.1080/09674845.2007.11732749

46. Rodríguez-Morán M, Guerrero-Romero F. Low serum magnesium levels and foot ulcers in subjects with type 2 diabetes. *Arch Med Res* (2001) 32:300–3. doi: 10.1016/S0188-4409(01)00298-3

47. Tiwari S, Pratyush DD, Gupta B, Dwivedi A, Chaudhary S, Rayicherla RK, et al. Prevalence and severity of vitamin d deficiency in patients with diabetic foot infection. *Br J Nutr* (2013) 109:99–102. doi: 10.1017/S0007114512000578

48. Tiwari S, Pratyush DD, Gupta SK, Singh SK. Vitamin d deficiency is associated with inflammatory cytokine concentrations in patients with diabetic foot infection. *Br J Nutr* (2014) 112:1938–43. doi: 10.1017/S0007114514003018

49. Yadav C, Srikantiah RM, Manjrekar P, Shenoy MT, Chaudhury D. Assessment of mineral pathophysiology in patients with diabetic foot ulcer. *Biol Trace Elem Res* (2020) 195:366–72. doi: 10.1007/s12011-019-01868-3

50. Singh S, Sahay R, Krishna A. Oxidative stress in diabetic foot ulcer. Diabetes Metab Syndr: Clin Res Rev (2008) 2:109-13. doi: 10.1016/j.dsx.2008.02.003

51. Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res (2010) 89:219–29. doi: 10.1177/0022034509359125

52. Stechmiller JK. Understanding the role of nutrition and wound healing. *Nutr Clin Pract* (2010) 25:61–8. doi: 10.1177/0884533609358997

53. Amini MR, Aalaa M, Nasli-Esfahani E, Atlasi R, Sanjari M, Namazi N. The effects of dietary/herbal supplements and the serum levels of micronutrients on the healing of diabetic foot ulcers in animal and human models: a systematic review. J Diabetes Metab Disord (2021) 20:973–88. doi: 10.1007/s40200-021-00793-4

54. Contreras-Bolívar V, García-Fontana B, García-Fontana C, Muñoz-Torres M. Mechanisms involved in the relationship between vitamin d and insulin resistance: impact on clinical practice. *Nutrients* (2021) 13:3491. doi: 10.3390/nu13103491

55. Dai J, Jiang C, Chen H, Chai Y. Vitamin d and diabetic foot ulcer: a systematic review and meta-analysis. Nutr Diabetes (2019) 9:1–6. doi: 10.1038/s41387-019-0078-9

56. Szymczak I, Pawliczak R. The active metabolite of vitamin D3 as a potential immunomodulator. *Scand J Immunol* (2016) 83:83–91. doi: 10.1111/sji.12403

57. Bishop E L, Ismailova A, Dimeloe S, Hewison M, White JH. Vitamin d and immune regulation: antibacterial, antiviral, anti-inflammatory. *JBMR plus* (2021) 5: e10405. doi: 10.1002/jbm4.10405

58. Qu G-B, Wang L-L, Tang X, Wu W, Sun Y-H. The association between vitamin d level and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus: An update systematic review and meta-analysis. *J Clin Transl Endocrinol* (2017) 9:25–31. doi: 10.1016/j.jcte.2017.04.001

59. Basit A, Basit KA, Fawwad A, Shaheen F, Fatima N, Petropoulos IN, et al. Vitamin d for the treatment of painful diabetic neuropathy. *BMJ Open Diabetes Res Care* (2016) 4:e000148. doi: 10.1136/bmjdrc-2015-000148

60. Alam U, Nelson AJ, Cuthbertson DJ, Malik RA. An update on vitamin d and b deficiency in the pathogenesis and treatment of diabetic neuropathy: a narrative review. *Future Neurol* (2018) 13:135–42. doi: 10.2217/fnl-2017-0034

61. Sugden J, Davies J, Witham M, Morris A, Struthers A. Vitamin d improves endothelial function in patients with type 2 diabetes mellitus and low vitamin d levels. *Diabetes Med* (2008) 25:320–5. doi: 10.1111/j.1464-5491.2007.02360.x

62. Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J (2012) 5, Suppl. 1:i3–14. doi: 10.1093/ndtplus/sfr163

63. Chaudhary DP, Sharma R, Bansal DD. Implications of magnesium deficiency in type 2 diabetes: a review. *Biol Trace Elem Res* (2010) 134:119–29. doi: 10.1007/s12011-009-8465-z

64. Liu M, Dudley SC Jr. Magnesium, oxidative stress, inflammation, and cardiovascular disease. Antioxid (Basel) (2020) 9:907. doi: 10.3390/antiox9100907

65. Strom A, Strassburger K, Schmuck M, Shevalye H, Davidson E, Zivehe F, et al. Interaction between magnesium and methylglyoxal in diabetic polyneuropathy and neuronal models. *Mol Metab* (2021) 43:101114. doi: 10.1016/j.molmet.2020.101114

66. Jamali AA, Jamali GM, Tanwani BM, Jamali AA, Tanwani Y, Jamali NM. Association of hypomagnesemia in type 2 diabetic patients with and without peripheral neuropathy. *J Diabetes Mellitus* (2018) 8:27–42. doi: 10.4236/jdm.2018.82004

67. Zhang J, Zhang B, Zhang J, Lin W, Zhang S. Magnesium promotes the regeneration of the peripheral nerve. *Front Cell Dev Biol* (2021) 9:717854. doi: 10.3389/fcell.2021.717854

68. Moon K-C, Kim S-B, Han S-K, Jeong S-H, Dhong E-S.. Risk factors for major amputation in hospitalized diabetic patients with forefoot ulcers. *Diabetes Res Clin Pract* (2019) 158:107905. doi: 10.1016/j.diabres.2019.107905

69. Coger V, Million N, Rehbock C, Sures B, Nachev M, Barcikowski S, et al. Tissue concentrations of zinc, iron, copper, and magnesium during the phases of full thickness wound healing in a rodent model. *Biol Trace Element Res* (2019) 191:167–76. doi: 10.1007/s12011-018-1600-y

70. Harding A-H, Wareham NJ, Bingham SA, Khaw K, Luben R, Welch A, et al. Plasma vitamin c level, fruit and vegetable consumption, and the risk of new-onset type 2 diabetes mellitus: the European prospective investigation of cancer-Norfolk prospective study. *Arch Intern Med* (2008) 168:1493–9. doi: 10.1001/ archinte.168.14.1493

71. Mohammed BM, Fisher BJ, Kraskauskas D, Ward S, Wayne JS, Brophy DF, et al. Vitamin c promotes wound healing through novel pleiotropic mechanisms. *Int Wound J* (2016) 13:572–84. doi: 10.1111/iwj.12484

72. Devanandan P, Puvvada RC, Muthukumar VA. Association of vitamin c status in diabetes mellitus: prevalence and predictors of vitamin c deficiency. *Future J Pharm Sci* (2020) 6:1–5. doi: 10.1186/s43094-020-00040-2

73. Ashor AW, Lara J, Mathers JC, Siervo M. Effect of vitamin c on endothelial function in health and disease: a systematic review and meta-analysis of randomised

controlled trials. *Atherosclerosis* (2014) 235:9-20. doi: 10.1016/j.atherosclerosis.2014.04.004

74. Gunton JE, Girgis CM, Lau T, Vicaretti M, Begg L, Flood V. Vitamin c improves healing of foot ulcers: a randomised, double-blind, placebo-controlled trial. *Br J Nutr* (2021) 126:1451–8. doi: 10.1017/S0007114520003815

75. Moores J. Vitamin c: a wound healing perspective. Br J Community Nurs (2013) 18:S6–S11. doi: 10.12968/bjcn.2013.18.Sup12.S6

76. Yarahmadi A, Saeed Modaghegh M-H, Mostafavi-Pour Z, Azarpira N, Mousavian A, Bonakdaran S, et al. The effect of platelet-rich plasma-fibrin glue dressing in combination with oral vitamin e and c for treatment of non-healing diabetic foot ulcers: a randomized, double-blind, parallel-group, clinical trial. *Expert Opin Biol Ther* (2021) 21:687–96. doi: 10.1080/14712598.2021.1897100

77. Dixit R, Chaudhary NK, Mishra PK, Srivastava P, Bhartiya SK, Pratap A, et al. Study on blood serum levels of heavy and trace metals in chronic non-healing wounds. *Int J Low Extrem Wounds* (2022). doi: 10.1177/15347346221074161

78. Bajpai S, Mishra M, Kumar H, Tripathi K, Singh SK, Pandey HP, et al. Effect of selenium on connexin expression, angiogenesis, and antioxidant status in diabetic wound healing. *Biol Trace Element Res* (2011) 144:327–38. doi: 10.1007/s12011-011-9097-7

79. Nelson SM, Lei X, Prabhu KS. Selenium levels affect the IL-4-induced expression of alternative activation markers in murine macrophages. J Nutr (2011) 141:1754–61. doi: 10.3945/jn.111.141176

80. Duntas LH, Benvenga S. Selenium: an element for life. *Endocrine* (2015) 48:756–75. doi: 10.1007/s12020-014-0477-6